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ABSTRACT 
DEVELOPMENT OF STRUCTURE-BASED DRUG DESIGN MODULE FOR 
BIOENGINEERING LAB 
by 
Aarthi Janakiraman 
This thesis is focused on the development of a laboratory module for structure-
based drug design. The process of structure-based drug design is thoroughly explored 
and simplified into five steps involving choosing the target, visualizing the target 
structure, identifying the binding site, docking the ligands, and evaluating them. The 
drug design for osteoarthritis was performed using the COX-2 enzyme as the drug target. 
Five ligand compounds, acetyl salicylic acid, rofecoxib, celecoxib, SC-558, and 
fucoxanthin were docked to the drug target individually with the help of UCSF DOCK 
software. Three ligands (rofecoxib, celecoxib, SC-558) unambiguously showed selective 
affinity for COX-2. The docked ligands, when evaluated using Lipinski's analysis, 
showed less absorption capabilities with increase in molecular weight and partition 
coefficient. 
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CHAPTER ONE 
INTRODUCTION 
Modern medicine has made tremendous leaps in the field of drug discovery. The 
drug design industry is now one of the major players in the bioinformatics and 
biotechnology industries. Many pharmaceutical companies have a biotech and a 
bioinformatics unit in their research departments. The past two decades have seen the 
development of numerous procedures to diagnose and treat patients. The objective of this 
thesis proposal is to prepare a laboratory module for drug design using bioinformatics 
tools. 
1.1 Economic Significance 
Drug research is comparatively less expensive than health care. The National 
Institute of General Medical Sciences (NIGMS) states that in 1990, research and 
developmental costs were only 3.7 % of health care costs [1]. Trying to cure a disease 
with insufficient research leads to unsuccessful treatment and soaring health care costs 
resulting in severe economic impact. Research is the step which reduces health care costs 
while potentially saving lives. 
Drug discovery is a time consuming process involving a lot of money. The 
process of discovering a drug and getting it approved by the FDA costs a pharmaceutical 
biotech company millions of dollars. In the year 1997, the top twenty pharmaceutical 
companies spent $16 billion on drug development alone [2]. Thousands of compounds 
were screened and studied in order to find one drug. On a positive note, when a drug is 
approved, the company gets billions of dollars in revenue and no other company can 
duplicate it, as it is patented for at least 20 years. For example, in 2000, Prilosec, a drug 
commonly used to treat stomach ulcers, earned $4,102 billion in sales [2]. 
1.2 Time Factor 
The development of any prospective drug begins with years of strenuous research 
to figure out the complexity of the medical problem. Often, it takes 5 years, minimum, to 
discover the drug, 2-5 years of preclinical testing, and 3-10 years of clinical testing. A 
patent is granted for 20 years at the end of the preclinical phase. The whole process takes 
5-10 years after which the drug is forwarded to the FDA (Food and Drug 
Administration) for final approval [3]. This means that the company is left with less than 
10 years to earn back the research and development cost before the patent expires. 
1.3 Drug Design 
The development of a new drug is called drug discovery. Drug design is the first 
step in drug discovery research. This is a process in which drugs are invented based on 
the disease. Drugs are usually designed in a manner to bind to, interact with, and affect 
the activity of the key molecule under study. 
Generally a pharmaceutical company aims to design a drug based on certain 
theoretical concepts but the effectiveness of this aspect is far from optimal. Drugs have 
been discovered accidentally, like penicillin. Another example of an accidentally 
discovered drug is Cisplatin [4]. The drug was discovered while a NIGMS (National 
Institute of General Medical Sciences) grantee was studying the effect of electric fields 
on bacteria. The researcher noticed that the platinum electrodes used in his experiment 
were inhibiting the bacteria from dividing. The platinum compounds had anti-tumor 
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effects and now Cisplatin is the leading drug used in treatment for testicular, ovarian and 
bladder cancers. Not all drugs have been found accidentally; most drugs are found after 
years of intensive research and hard work. 
1.4 Types of Drug Design 
There are two main types of research in drug design. The first method, called 
High Throughput Screening (HTS), identifies active compounds in collections or libraries 
as quickly as possible and with high statistical accuracy. Success in HTS depends on 
uncontrollable factors. For instance, HTS hits (successfully bound compounds) 
eventually decompose and some HTS hits have poor physico-chemical properties for use 
as potential drugs. Many compounds on the order of thousands or more must be tested to 
find a hit. 
The other method, structure-based drug design, involves detailed knowledge of 
the binding sites of targets (such as proteins) associated with the disease. A drug's 
effectiveness depends on structural interaction with the receptor or target molecule. The 
most common model is the one in which the drug molecule fits itself into the crevice of 
the target protein similar to a key in a lock. This strategy results in inhibition of the 
protein's function, and ultimately halts the progress of the disease. 
Structure-based drug design offers tremendous potential and a powerful 
alternative to traditional screening techniques. This drug design method involves basic 
knowledge of bioinformatics, proteomics, biochemistry, and computer modeling of 3-
dimensional protein structures. 
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1.5 AIDS Drug Design through Structure-based Approach 
Since many drugs have been discovered and developed in the past for treatment of 
AIDS (Acquired Immuno Deficiency Syndrome), it serves as an example for structure-
based drug design. In the 1980s, the world of medicine witnessed the AIDS disaster. 
Eventually, doctors realized that a killer virus was infecting and destroying the immune 
system of the body. 
In the late 1990s, deaths due to AIDS were drastically reduced when new drugs 
were introduced. Scientists determined the structure of HIV (Human Immunodeficiency 
Virus) protease and recognized that by inhibiting the enzyme, viral multiplication could 
be prevented. Researchers analyzed the HIV protease and developed drugs called 
Protease Inhibitors. These inhibitors prevented viral replication and prolonged the life 
span of AIDS patients. 
In structure-based drug design, the concept is to map every point in the protein 
molecule and deduce ways to stop the protein from working. Funded by the National 
Institute of General Medical Sciences (NIGMS), three drugs (Norvir, Fortovase, and 
Viracept) took eight years to come into the market through fast tracking by the Food and 
Drug Administration (FDA). Other HIV drugs can be found on the NIGMS website. 
Apart from those intended to be used for the treatment of AIDS, many other drugs were 
designed based on structure for diseases like glaucoma, arthritis, flu, breast cancer, and 
trypanosoma. 
The intention is to prepare a simple and a basic module on structure-based drug 
design for basic understanding of the drug design process for a bioinformatics graduate 
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course. This module will create an appreciation of the process of drug design and of how 
small molecules bind to the target macromolecule. 
CHAPTER TWO 
BACKGROUND 
2.1 Process of Structure-based Drug Design 
Structure-based drug design plays a major role in the development of novel drugs 
against many diseases. Recent advances in large scale determination of protein structures 
are improving the drug discovery process by starting with the protein structure and using 
it to design and identify new ligands. The objective of the background is to cover the 
significant steps involved in structure-based drug design. 
2.2 Steps Involved in Structure-based Drug Design 
1. Identification of drug target 
2. Determination of target structure 
3. Identification of binding site 
4. Computational drug design methods 
5. Evaluation of potential lead candidate 
2.2.1 Identification of Drug Target 
A drug target or a receptor is a macromolecule that is critical for a disease 
condition to happen. The identification of a drug target starts with understanding the 
structural biology of the target. Function prediction, pathway information, disease 
associations, and structural data need to be considered when choosing a drug target. 
Different bioinformatics tools are used to gather this information, helping to choose the 
potential target that is critical for the disease function. 
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The objective in drug development against pathogenic diseases is total inhibition 
leading to the death of the pathogen. The target should be located in a critical step of a 
metabolic pathway and its inhibition should consequently kill the pathogen. Drug targets 
should be unique so that no other pathway should suppress the impact of the inhibitor. 
One important criterion of a drug is specificity. The physiological effect of the drug 
should be as clearly defined as possible. It should specifically bind to the target protein 
in order to minimize undesired side-effects. 
2.2.2 Determination of Target Structure 
Accurate structural information is needed after the drug target is chosen. 
Knowing a protein's structure is vital to understanding how it functions. Following are 
three methods by which structural data is obtained. 
1. X-ray crystallography (XRC) 
2. Nuclear Magnetic Spectroscopy (NMR) 
3. Homology Modeling or Comparative Modeling 
X-ray crystallography (XRC) is an experimental technique in which X-rays are 
diffracted by crystals. XRC is the main source of information for drug design as it gives 
high resolution structures. Once the 3-dimensional structure of protein is determined, the 
co-ordinates of the atoms are used by the computer to construct the protein structure. 
Nuclear magnetic resonance (NMR) is a spectroscopic technique that uses 
magnetic fields and electromagnetic radiation to determine the structure of organic 
compounds. NMR is commonly used for characterizing the structure and molecular 
dynamics of target or ligand molecules. 
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Homology modeling finds the approximate 3-dimensional structure of the target 
(not determined either by X-ray or NMR technique) based on an available sequence, 
provided with an empirical structure template with at least 30% sequence identity. This 
method can be applied to generate reasonable 3-dimensional models of protein structures. 
2.2.3 Identification of Binding Site 
After structure of the target is determined, the binding site (also known as the 
active site) needs to be identified. The ligand is a small molecule which can be ingested 
orally. The binding site is a hollow cavity-like structure and has hydrogen bond donors 
as well as hydrophobic characteristics. When the ligand binds to the target at the binding 
site and is capable of inhibiting the target, then the ligand is considered a lead compound 
or lead candidate. 
2.2.4 Computational Drug Design Methods 
The goal of all computational studies used in drug design is to evaluate the 
inhibitor binding complex. After identifying the possible binding regions on a target 
structure, potential ligands that bind and inhibit the target are evaluated. Computational 
and experimental methods are followed for finding a good lead. Computational methods 
for structure-based drug design are not mature enough to replace existing practices, but 
new approaches and computer programs continue to appear. Most work falls into the 
categories of De novo design, Docking, and Scoring. 
De novo design involves designing of novel ligands intended to bind to a given 
receptor with high affinity. Researchers split the problem of ligand binding into two 
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sections; docking and scoring. For a known target structure and a known ligand, docking 
involves locating the bound configuration of the ligand and receptor, while scoring 
involves evaluating the affinity of the ligand, given a particular bound configuration. 
Docking and scoring are complementary methods in structure-based drug design. 
2.2.5 Evaluation of Potential Lead Candidate 
Once the ligand has been successfully identified, it is called the lead compound. 
It must be evaluated for binding affinity before proceeding to the preclinical trials. The 
lead is evaluated for bioavailability, oral viability, chemical and physical stability, and 
ease of production. 
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CHAPTER THREE 
LITERATURE REVIEW 
The field of drug design is a widely researched area with many successes since 
1980's. Every step in drug design requires tremendous research effort. This literature 
review discusses the popular methods and programs that were used to discover drug 
targets and to determine target structure. Computational drug design methods and 
concepts along with advantages and disadvantages are presented in this review for 
detecting ligand binding sites and docking the targets. The merits and demerits are also 
discussed in this section. 
3.1 Identification of Drug Target 
The drug targets in structure-based drug design are mostly proteins. The proteins 
belong to families of kinases, proteases, and peptides. Enzymes are exceptional drug 
targets because compounds can be found to fit into the active site. 
The most popular method for identifying drug targets is by the study of the 
disease under observation and by identification of genes associated with the disease. 
Coombs et al. in their review state that the P. falciparum Genome Project had identified 
several drug targets for malaria. They researched hemoglobin metabolism and found that 
enzymes called plasmepsins of Plasmodium falciparum (mosquito) were involved in 
hemoglobin degradation. They found that Plasmepsins 1, 2,4 and Histo Aspartic 
Protease (HAP) played a significant role in hemoglobin degradation and were potential 
drug targets [5]. Banerjee et al. suggested that proplasmepsin convertase could also be 
used as a promising drug target because it produces plasmepsins [6]. 
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Genomics related methodologies are applied for choosing drug targets. Sakharkar 
et al. used three-way genome comparisons to identify essential genes from Pseudomonas 
aeruginosa. The National Center for Biotechnology Information (NCBI) and Database of 
Essential Genes (DEG) databases were used for downloading the protein sequences for P. 
aeruginosa and humans. The P. aeruginosa genes were eliminated at 60% using 
pathogen genes without homologs in humans. An expectation (E-value) cutoff of 103 
was used and the non-homologous entries were then subjected to BLASTP (Basic Local 
Alignment Search Tool) against the DEG database for the identification of homologs to 
essential genes at a cutoff score of 1010. Their approach identified 306 essential genes 
that may be considered as potential drug targets for new antibiotics [7]. 
3.2 Structure Determination 
The 3-dimensional structure of HIV-I protease was extensively studied and 
characterized through XRC studies. It was the first breakthrough that made rational drug 
design for AIDS possible. The HIV protease structure was first determined in 1987 by 
Pearl et al. through homology modeling using the known structures of eukaryotic 
aspartic proteases as templates. They used structure prediction and molecular modeling 
techniques, concluding that the viral protease sequences correspond to a single domain of 
an aspartic protease, and that this domain may function in a dimeric form. The 
researchers also constructed a model of the pol-protease of HIV-1 to test this hypothesis 
[8]. 
Navia et al. from Merck laboratories achieved HIV protease structure in 1989 [9]. 
A more accurate model was reported by Kent and his co-workers from the National 
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Cancer Institute. They synthesized an active protease entirely out of D-amino acids that 
was able to catalyze the proteolysis of D-peptides [9]. Figure 1 shows the structure of 
HIV protease. 
Figure 1. Structure of HIV protease [Reprinted with permission from 
Dr.T.N.Bhat, "HIVdatabase PR gallery", available at 
http://xpdb.nist.gov/hivsdb/gallery.html]. 
In its mature form, the viral protease exists as a dimer, whose subunits each 
consist of 99 amino acids. The folded subunits together interact to form a hydrophobic 
core and two flexible flaps that can close around the substrate [10]. 
The above research work shows clearly that XRC and Homology Modeling 
techniques played a major role in structure determination. Currently there are more than 
140 HIV protease structures available in the online database of the National Cancer 
Institute. The RCSB protein data bank currently has 40,354 biological macromolecular 
structures stored in the database [11]. Most researchers download structures for their 
study from this information portal for molecular modeling purposes. 
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3.3 Identification of Binding Site 
Kuniyasu identified the binding sites using the photoaffinity labeling method. 
The binding sites of four typical calcium antagonists, 1,4-dihydropyridines, 
benzothiazepines, phenylalkylamines, and benzothiazines, were successfully identified 
within the primary structure of the skeletal muscle calcium channels [12]. 
Co-crystallization studies in which the target molecule is crystallized with a small 
bound molecule inhibitor can be valuable to determination of the target site. Filikov et al. 
identified three ligand binding sites for RNA targets in HIV-1 TAR using virtual 
screening [13]. 
Computational tools have been developed to detect the ligand binding sites or the 
depressions in the target surface in order to localize the potential binding sites. These 
methods rely on purely geometric criteria with different algorithmic approaches. There 
are three cavity identification programs, namely: LIGSITE [14], APROPOS (Automatic 
PROtein POcket Search) [15], and PASS (Putative Active site with Spheres) [16]. 
Hendlich et al. developed LIGSITE which embeds the protein in a uniformly 
spaced grid. Lattice intersections that coincide with the protein atom's Van der Waals 
sphere are discarded. The remaining lattice points are scored according to their degree of 
burial in surface depressions [14,17]. 
Though all the above cavity identification programs are freely accessible to all, 
most of the docking software provides similar programs as an accessory. In addition, 
most of the binding studies are available in scientific journals and databases. With the 
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information provided in the databases, there is less need to use the cavity identification 
software. 
3.4 Computational Drug Design 
De novo design is the generation of new compounds that do not exist in 
compound databases. This means that the ligand structure is not known. Many programs 
were created for de novo drug design. Bohm developed a new method for de novo design 
of inhibitors called LUDI which can attach a new substituent into an already existing 
ligand. The application was used for binding HIV protease inhibitors and inhibitors of 
dihydrofolate reductase. The LUDI algorithm suggested modifications to increase the 
binding affinity between an existing ligand and target [18,19]. 
The LUDI algorithm represents a molecular-fragment based approach to 
identifying potential de novo leads. Fragments are identified that make hydrogen bonds 
with the target and fill hydrophobic pockets on the target, and the fragments are then 
connected with linkers to make a single molecule. The matching process is performed 
using the fragment library for the binding site. The matching fragment is then docked for 
alignment. The method was tested with dihydrofolate reductase (DHFR) and trypsin, and 
was found to generate fragments that aligned favorably with known inhibitors such as 
methotrexate and benzamidine [18,19]. 
The other de novo design programs are SPROUT [20], HOOK [21], Growmol 
[22], GRID [23], CAVEAT [24], and Legend [25]. These programs generate new 
structures that fit the site of the target, but have two common critical defects; the 
synthetic feasibility of the novel structures is not considered and the prediction of binding 
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affinity is not accurate. These defects make it difficult to obtain the new compounds 
from de novo generation. One of the defects (prediction of binding affinity) can be 
overcome by using the scoring function. The formula is as follows: 
- RT In Kd = AG° = AH° - T AS° Equation 1 
Where R is the gas constant at the absolute temperature T, Kd is the dissociation 
constant of a ligand-target complex and measures binding affinity, and AH0 and AS°are 
the changes in standard enthalpy and entropy. AG° is the change in standard Gibbs free 
energy. 
The principle of free energy perturbation and molecular dynamics simulation was 
reported by Kollman et al. Free energy perturbation (FEP that could be used to calculate 
binding affinity for similar compounds) and molecular dynamic simulations were both 
time consuming [26]. The researchers, in order to overcome this defect, developed the 
generalized Born model and the Ligand Interaction Energy (LIE) for computational speed 
and accuracy of binding affinity. 
The interaction of inhibitors with HIV protease was the beginning for various 
docking methods. The first docking method was developed by Kuntz et al. They 
discovered that haloperidol could be used as an inhibitor for the HIV protease. As the 
structure prediction of the inhibitor turned out to be different from the predicted one, 
haloperidol was not used [27,28]. 
To predict binding sites in a target, DOCK software was used. DOCK software 
predicted the binding modes of small molecule-protein complexes. First, the potential 
sites of interest on the target molecule are identified. The molecular surface area of the 
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target is generated and a negative image of the surface is created around the active site. 
Sphere centers are then matched to the ligand atoms, for possible orientations. Typically, 
tens of thousands of orientations are generated for each ligand molecule. The orientation 
of the ligand is evaluated using scoring grids. Scoring grids are pre-calculated energy 
information for each atom of the target. The ligand-receptor binding energy is the sum of 
van der Waals attractive, van der Waals dispersive, and columbic electrostatic energies. 
As a result, interpolated receptor values are obtained. Finally when docking is 
performed, the ligand values are substituted and the orientation of the ligand is evaluated 
based on the lowest energy score for effective binding [29]. 
DOCK runtimes depend on many variables, including the number of ligands 
being explored, ligand size, target size, and sampling parameters. It can take anywhere 
from a few seconds for a single ligand to a number of days for large databases. The 
following page shows how DOCK works with Figure 2, Figure 3, and Figure 4. 
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Figure 2. Spheres generated over negative image of receptor surface. 
Figure 3. Energy grid for target is calculated. 
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Figure 4. Docked molecule with multiple ligands. 
3.5 Drug Lead Evaluation 
Lipinski's Rule of 5 is followed for the lead drug evaluation [30]. It is called 
Rule of 5 because all the four parameters evaluated are close to five or a multiple of 5. 
Lipinski states that poor absorption or permeation is more likely when 
> There are more than five H-bond donors. 
> The molecular weight is over 500 Da. 
> The logP (partition coefficient) is over 5. 
> The sums ofN's and O's are over 10. 
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Veberetal. state that the number of rotatable bonds should be less than 10 and 
the H-bond donors or acceptors should be less than 12 for oral bioavailability [31]. 
19 
3.6 Summary 
Structure-based drug design is a powerful method for discovering new drugs 
against diseases. From the literature review we see that XRC and homology modeling 
are excellent tools for structure determination. The structures stored in the databases are 
an ideal choice for selecting and downloading the structures of the macromolecule. The 
same applies to the ligand as well. In the case of target site identification and drug target, 
literature search is the best option; there is a wealth of information available on the 
internet and the electronic databases. Purely geometric tools for binding site 
identification are generally well suited to localize all significant cavities or depressions 
on the protein surface. The UCSF DOCK software is found to be a simple, effective and 
representative tool. For the ligand evaluation stage, the Lipinski's Rule of Five and the 
number of rotatable bonds are used. 
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CHAPTER FOUR 
RESEARCH OBJECTIVES AND JUSTIFICATIONS 
4.1 Research Objectives 
The research objective of this thesis is to develop a laboratory module in order to 
introduce basic principles of drug design. The module is intended to be used in a 
graduate level, bioinformatics or bioengineering class as lab work in the chemical 
engineering department of SJSU. It is important for students who aim to enter into a 
biotech industry to have basic practical knowledge of drug design. 
The bioinformatics lab course covers practical and theoretical concepts of 
genomics, proteomics, and relevant bioinformatics tools. Students will work on the drug 
design lab module based on techniques and skills they have learned throughout the 
semester. This exercise will help them get familiar with the bioinformatics tools 
employed in various applications. To understand drug research concepts, there will be 
five main modules based on the process of structure-based drug design. The key goals of 
the module will be 
> To identify the drug target 
> To visualize the drug target 
> To find ligand candidates that uniquely interact with the target 
> To dock the ligand with the drug target 
> To evaluate the docked ligand 
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4.2 Justifications 
> The faculty of chemical engineering at SJSU suggested incorporating a drug 
design module into the bioinformatics course as students only learned basic 
practical concepts to a limited extent without it. 
> The module has been carefully developed. It is cost effective, as the chosen 
software is free to academic users. 
> The students do not require any programming skills, except the knowledge of 
UNIX commands, as the drug design module is very user-friendly. 
Even though the drug design module is brought together in a simple mode, it is 
still an ambitious effort. This module will evoke interest among students once they 
complete it; hence, they will further develop the module or use the tools in the module to 
facilitate their own bioinformatics research. 
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CHAPTER FIVE 
METHODS AND MATERIALS 
A student module was developed to give students an exposure to the drug design 
process. The module includes steps to follow for the procedure and the activities. The 
activities contain a small research project and questions at the end of the module to help 
students understand the process of drug design. The drug design lab module is presented 
in Appendix B. This section explains the materials and methods required to develop the 
module. 
5.1 Module Flowchart 
Figure 5 gives an overview of the structure of the modules. 
Drug Target 
Identification Module 
Target Structure 
Determination Module 
Ugand Binding Site 
identification Module 
Ligand Target Docking 
Module 
Lead Evaluation 
Module 
Figure 5. The drug design module flowchart. 
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5.2 Materials Required 
All the materials and software for the modules are readily available. The 
following information was required to develop and work the module: 
1. An uncomplicated human disease and its pathway 
2. The drug targets associated with the human disease 
3. A 3D molecular graphics program-VEGA ZZ 
4. The literature information regarding binding sites 
5. A basic docking software- UCSF DOCK 
6. The lead evaluation criterion 
The constant factors used in this module are the disease and the chosen drug 
target. The variable factors are the ligands. The names of the ligands are not disclosed to 
the students so that they can evaluate them purely based on their structures. A 3D 
molecular graphics software called VEGA ZZ and docking software called DOCK were 
used. The complete information for the software can be obtained on the internet. 
As for the module, a clear set of instructions has been provided along with the 
background information. A set of questions and activities has been developed at the end 
of each module. The questions and activities aim to make the students understand the 
process of drug design and encourage them to use bioinformatics tools. 
5.3 Drug Target Identification Module 
In this module the students' objective is to evaluate the drug targets in 
relationship to the disease and identify the best target. Information regarding the drug 
targets, such as function, disease pathway, and background, is presented to them. The 
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disease pathway provided to them will guide them indirectly towards the right answer. 
This module helps them understand the process of identifying a proper target for a 
specific disease and allows them to get a foothold in the design process. 
5.4 Target Structure Determination Module 
The student objective of this module is to determine the 3-dimensional structures 
of the target. This involves structure visualization and validation. A simple tutorial was 
developed for students to determine the target structure with the help of a molecular 
graphics program. Determining the target structure and viewing it will help the students 
understand the components of the target on a molecular level. Questions at the end of the 
module will help students understand the structural details. 
5.5 Ligand Binding Site Identification Module 
The student objective of this part of the module is to find potential ligand binding 
sites in the chosen drug target structure. Since there was considerable information about 
the active site presented in scientific journals, no software was required. The students are 
asked to do a literature search to find the active site(s) and their exact location using the 
electronic research databases provided in the SJSU library. This module will help them 
analyze the active site of the target structure in great detail. 
5.6 Ligand and Target Docking Module 
The student objective was to bind the ligand with the target structure 
geometrically using the docking software. The ligands were downloaded from the 
KEGG (Kyoto Encyclopedia of Genes and Genomes) Ligand Database website. This 
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module will help the students learn and appreciate the complex of two molecules via 
docking. This module is comprised of four stages outlined below. 
• Molecule preparation for ligand and receptor 
• Sphere generation of the receptor 
• Scoring grids for the receptor 
• Docking the receptor and ligand 
The manual provided by docking software was followed for this module. 
Students will perform ligand protein docking and will evaluate the parameters needed for 
this module. 
5.7 Potential Lead Evaluation Module 
The student objective of this module is to evaluate the ligand and to find the best 
lead. An evaluation criterion to analyze ligands is listed in the module. It is up to the 
students' discretion to find a lead and discuss why it is a good one. 
It is not unusual to obtain erratic results and conclusions due to many factors. The 
initial target selected may not have been a good one; in this case another target may be 
selected. The target site identification and analysis may not be correct. This is easily 
rectified by picking another target site. If and when this happens, the students will re-
evaluate their drug target or find another ligand binding site and will perform another set 
of experimental runs. 
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CHAPTER SIX 
RESULTS AND DISCUSSION 
The disease state taken up for study in this module is Osteoarthritis. This disease 
affects almost 21 million adults, in the United States alone. Osteoarthritis was chosen 
because it has several drug targets with specific function and pathway information that is 
simple to understand. Many drugs have been found that are used to treat the disease, and 
researchers are still in the process of finding a cure. Numerous targets are associated 
with arthritis ranging from enzymes to hormones, chemokines, and cytokines. All these 
target molecules generate pain signals. A lot of structural and functional information 
about target molecules are essential for choosing the right target upon which the drug can 
act. 
6.1 Background of Disease in Study 
Osteoarthritis is a chronic disease of the joints involving breakdown of the joint 
tissue, primarily the cartilage. Cartilage is a tough elastic tissue covering the bone that 
acts as a shock absorber and keeps the bones from rubbing against each other. The entire 
joint is enclosed in a capsule that is lined by an inner membrane known as the synovial 
membrane. The membrane fills the space around the joints with a fluid called the 
synovial fluid. The synovial fluid nourishes the cartilage and keeps the joints lubricated 
making movement smooth and easy. Enclosing the joints are muscles, tendons and 
ligaments. These structures provide support and assist movement in the correct direction. 
Figure 6 shows the difference between a normal joint and a degenerative joint. 
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Figure 6. Comparison of a normal joint and osteoarthris joint[diagram by author]. 
The degeneration of the cartilage causes inflammation. Inflammation is one of 
the ways in which the body protects and repairs itself. The inflammatory reaction begins 
with tissue irritation. In response to tissue irritation, white blood cells rush from the 
bloodstream to the area in order to facilitate the healing. They release enzymes and 
active products that affect the nearby cells and alter the blood circulation. The active 
products are prostaglandins and leukotrines. They are the potent producers of 
inflammation. They increase the flow of fluids and white blood cells around the area of 
inflammation and release more prostaglandins thereby feeding the process. The 
accumulation of these fluids and cells causes swelling along with pain [32]. 
There has been a lot of research regarding the cure of osteoarthritis. To date, 
there has been no clinically approved drug to cure it. Pain relievers such as analgesics 
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and NSAIDs (Non-Steroidal-Anti-Inflammatory-Drugs) are used for temporary pain 
relief. These medications cause as many side effects as benefits. Treatment for 
osteoarthritis is aimed at controlling pain, improving and maintaining movement, and 
preventing degeneration of the joints. Pain control is a vital part of the treatment as the 
drugs help the patient gain control over the effects of the disease. Rest and exercise help 
in maintaining movement and preventing degeneration of the joints. 
The drug targets that were chosen for study (along with the pathway description) 
are as follows. 
1. Cyclooxygenase enzyme-1 (COX-1) 
2. Cyclooxygenase enzyme-2 (COX-2) 
3. Prostaglandins 
4. Interleukin-1 receptor 
Prostaglandins are hormones that act as chemical messengers inside the cell 
activating inflammatory responses and strengthening pain signals. They are unsaturated 
carboxylic acids consisting of a twenty-carbon skeleton and a five-membered ring. They 
are synthesized from arachidonic fatty acid. In physiological conditions archidonic acid 
exists in the ionic form, hence is named arachidonate. This initial reaction in their 
generation is catalyzed by enzymes called cyclooxygenases (COX-1 and COX-2). The 
prostaglandins are essential for cytoprotection in the stomach, platelet aggregation and 
renal function. Prostaglandins produced by COX-2 cause inflammation. 
There are two different cyclooxygenases (COX-1 and COX-2). Both the enzymes 
perform the first step in production of prostaglandins by adding two oxygen molecules to 
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arachidonate. COX-1 and COX-2 enzymes shown in Figure 7 are similar in structure and 
have the same substrate (arachidonate). The kinetics of both the isoforms are similar but 
they obtain arachidonate from different sources. 
Figure 7. The structure of COX-1 (cyan) and COX-2(magenta) enzymes. 
The COX-1 enzyme is a constitutive enzyme, is present in all cells in the 
endoplasmic reticulum and is maintained at a constant level. The COX-1 enzyme is a 
"housekeeping enzyme" involved in signaling, tissue homeostasis and cytoprotection. 
Most importantly, it produces prostaglandins in the stomach to help maintain mucosal 
epithelium, and its inhibition cause gastric damage, bleeding, and ulcers. COX-1 
initiated prostaglandins are required to maintain normal renal blood flow in impaired 
kidneys. Prostaglandins synthesized with the aid of COX-1 are essential for platelet 
function. 
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The COX-2 enzyme is an induced enzyme. An inducer can increase its 
concentration in the range of 10-80, however this is reduced considerably after a few 
hours. It is found in high concentrations around macrophages, synovial cells, mucocytes, 
and fibroblasts in response to inflammation. The COX-2 enzyme is characteristic of 
increased inflammation when the system is trying to heal the inflamed area. 
The fourth drug target is the Interleukin-1 receptor that belongs to a family of 
cytokines. Cytokines are small secreted proteins which are pro-inflammatory. They 
contribute to the bone degeneration characterizing arthritis. The Interleukin-1 receptor is 
present in the synovial lining of the joint. The main function of this particular cytokine is 
to cause inflammation by activating monocytes and macrophages. Interleukin-1 
stimulates the production of prostaglandins and nitric oxide, and promotes joint 
degradation. The expression of Interleukin-1 can be stimulated by various types of cell 
interactions such as TNF, autocrine or paracrine. When one type of cytokine is inhibited 
the other cytokines replace it and carry on its function. Other cytokines having pro-
inflammatory properties or catabolic factors could also contribute to this pathological 
condition, and those that have anti-inflammatory properties may be able to counteract the 
negative effects of the former on the disease process. 
6. 2 Choosing the Right Drug Target 
There are several possible modes of drug-based therapy. These include targeting 
prostaglandins, the two enzymes COX-1 and COX-2 associated with prostaglandins 
synthesis, and the Inter-leukin receptor. The module helps students choose the right drug 
target based on available literature information. The analysis is as follows: 
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When analyzing the given drug targets, it is apparent that prostaglandins which 
are responsible for pain cannot be the target because their production is initiated by two 
different cyclooxygenases which generate different classes of prostaglandins. The 
prostaglandins produced by COX-1 are essential for cytoprotection in the stomach, 
platelet aggregation and renal function. Prostaglandins produced by COX-2 cause 
inflammation. If prostaglandins are inhibited it would not only stop inflammation but 
also stop positive functions of the body and cause damaging side effects. Hence 
prostaglandins cannot be used as a drug target. 
Cytokines cannot be used as a drug target because specific blockage of the 
Interleukin-1 receptor causes other cytokines to replace its function. Therefore, it would 
not be a worthwhile strategy to inhibit the Interleukin-1 receptor. 
It is evident that the COX-1 enzyme also cannot be used as a drug target because 
inhibiting this cyclooxygenase isoform causes gastric damage, hemorrhaging, and 
ulceration in the stomach. The inhibition also causes irregular blood flow in the kidney 
and platelet dysfunction in the circulatory system. COX-1 (present in all cells) is 
important for cell functions such as homeostasis. 
Although COX-1 and COX-2 enzymes are 60% similar in structure they carry out 
different functions; one maintains normal, cellular physiology while the other initiates the 
generation of pain. The COX-2 enzyme is up regulated during inflammation and is 
usually present in insignificant amounts in the human system; hence its inhibition would 
not affect the regular functions of the body. Since the aim of treatment is pain control 
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with few side effects, the COX-2 enzyme is the ideal drug target. Inhibition of the COX-
2 enzyme would result in anti-inflammatory and analgesic effects. 
6. 3 Determination of Target Structure 
After the students choose the right target, the next step is to determine the target 
structure. The students are required to visualize and obtain first hand information about 
the target in study. The drug target for this case study is cyclooxygenase-2 (COX-2). 
The structure of COX-2 is visualized using VEGA ZZ, an interactive molecular graphics 
program. VEGA ZZ is a new molecular modeling program widely used and free of 
charge for academic users. It is an interactive, user friendly program mainly used to 
visualize biomolecules. Additionally, it performs tasks like adding hydrogen, deleting 
solvent, adding charges and changing the file format. Since the modeling program is also 
useful for docking purposes, it has been used in the fourth stage of the module as well. 
The software is available online and can be downloaded and installed from the website 
http://www.ddl.unimi.it. UCSF Chimera is another similar molecular modeling program 
that has been used scarcely. 
The COX-2 crystallographic structure is obtained from RSCB protein data bank 
which contains information about macromolecular structures in pdb format. Every 
molecule is denoted by a pdb id. An uninhibited mouse COX-2 structure is used as the 
target. The corresponding pdb id is 5COX.pdb. This target structure (5COX) is used 
because it is similar to that of the human COX-2 structure (87% similarity) and a 
compatible human COX-2 structure was not available in the database [33]. Most 
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researchers have worked with the mouse structure in the drug design phase. The 
structure of cyclooxygenase-2 is viewed in the VEGA ZZ program shown in Figure 8. 
Figure 8. The structure of COX-2 enzyme. 
The basic characteristics of COX-2 are listed below. 
• The COX-2 structure is a homodimer of identical subunits. It is comprised 
of four protein chains and 587 amino acids. The four protein chains are 
indicated in blue, green, red and white shown in Figure 12. The structure 
contains four heme ligands and 12 N-acetyl glucosamine (NAG) 
trisaccharide ligands shown in yellow in Figure 8. 
• The heme group is protoporphyrin IX containing iron (Fe). The metal free 
porphyrin combines with the ferrous ion to form the heme group.The 
enzyme has a cyclooxygenase active site and the peroxidase active site 
separated by a heme prosthetic group. 
6.4 Determination of the Target Active Site 
After the determination of the target structure, the students are led to the third 
stage of determining the active site of the target. There is ample information about the 
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location of the active site and its function on the internet. The structure of the drug target 
is loaded into VEGA ZZ and with the information given from the journals the active site 
is located. Since there are two active sites, students are indirectly guided to find the 
correct active site. A literature search was performed in the electronic database provided 
by the SJSU library. The keywords used were "COX-2 + active site + location." Figure 
9 shows the location of the active site enclosed by residues. 
Figure 9. The COX-2 structure with active site surrounded with white residues. 
The COX-2 enzyme structure has two different active sites, the cyclooxygenase 
active site and the peroxidase active site. At the cyclooxygenase active site, arachidonate 
binds to form prostaglandin (cyclopentane hydroperoxy endoperoxide; PGG2). If 
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arachidonate is prevented from binding, then prostaglandins will not be formed, hence no 
inflammation will occur through COX-2. 
The peroxidase active site converts the peroxide in PGG2 into an OH group 
transforming PGG2 to PGH2. This active site is needed to produce a tyrosyl radical in 
newly synthesized COX (Tyr 384 in COX-1 and Tyr 371 in COX-2) that participates in 
the cyclooxygenase reaction. This tyrosyl radical is radical is critical to the reaction 
catalyzed by cycloxygenase and is regenerated by the catalytic well. The cyclooxygenase 
active site is chosen to be the right active site and will be used for the docking stage. 
The cyclooxygenase active site is defined by three different regions. There is a 
hydrophobic pocket area surrounded by residues tyrosine385, tryptophan 387, 
phenylalanine 518, tyrosine 248, and leucine 352. The entrance of the active site is 
defined by arginine 120, Glu 524, and tyrosine 355 and there is a side pocket enclosed by 
valine 523, arginine 513 [34]. Since the valine molecule is small, it leaves a gap causing 
a side pocket. This side pocket is the site of binding for many selective drugs. 
6.5 DOCK 
After analyzing the COX-2 active site, the students are guided to the fourth stage 
called the docking stage. In this stage molecular docking software called DOCK is used. 
The students will be given reference instructional manual to operate of the software and 
will proceed with the docking process. 
The UCSF DOCK software was chosen for docking purposes. The manual 
provided by DOCK was followed for the docking procedure. Test runs for ligand protein 
docking were performed and the parameters needed for this module were evaluated. 
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6.5.1 Overview 
The DOCK software predicts the binding modes of small molecule-protein 
complexes. The docking part is divided into series of steps. First, the potential sites of 
interest on the target molecule are identified using the negative image of the target 
structure. The sites of interest include the active site as well as the other potential 
binding sites. This means it does not differentiate between the actual active site and the 
other potential sites. 
Secondly, the software generates spheres which fill the sites of interest chosen by 
DOCK. The sphere centers are assumed to be ligand atom positions. The spheres touch 
the surface of the molecule but do not intersect it. The spheres are allowed to overlap or 
intersect other spheres. Figure 10 shows how spheres are arranged in a sample binding 
site. The blue spheres are generated with the help of points from molecular surface 
indicated by the green line [35]. 
Figure 10. Representation of the spheres arranged in a binding site. [Reprinted with 
permission from Dr.Irwin Kuntz and Dr.Therese Lang, "Tutorial: generating spheres", 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/sphere_generation/generating_spheres.ht 
m] 
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After the spheres are generated, the sphere centers are "matched" with the ligand 
atoms in order to position a ligand in the active site. Many such sphere-ligand atom sets 
are formed using the longest distance heuristic method. The entire orientation of the 
ligand atom within the active site is calculated using sphere-ligand atom sets [36]. 
Thirdly the ligand orientation is evaluated using scoring grids. Scoring grids are 
pre-calculated energy information for each atom of the target. Every atom of the target 
has an associated ligand-target binding energy and an electrostatic charge. As a result, 
interpolated receptor values are obtained. Finally when docking is performed, the ligand 
values are substituted and the orientation of the ligand is evaluated based on the lowest 
energy score for effective binding [36]. 
There are two types of docking, flexible and rigid. In rigid docking, the receptor is 
assumed to be a rigid structure that does not flex itself to fit the ligand [36]. In flexible 
docking, it is assumed that the receptor structure can change its shape to align with the 
ligand during docking. 
A standard method for docking described in the UCSF DOCK manual was 
followed. The starting data are COX-2 and ligand structures. To dock the target structure 
a step by step procedure was followed. 
1. Molecule preparation for target and ligand 
2. Sphere generation of the target 
3. Scoring grids for the target 
4. Docking the target and ligand 
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6.5.2 Molecule Preparation for Target and Ligand 
The purpose of this step is to prepare the target and the ligand molecule as an 
input to DOCK. For the target structure (which is a homodimer) only one subunit of 
COX-2 is required. Using the "Remove Segment" option in VEGA ZZ, all chains except 
one are deleted. Figure 11 shows a single chain structure of COX-2. 
Figure 11. Single chain of COX-2 structure. 
With the help of the "edit" option in VEGA, minor modifications are executed. 
The minor changes are solvent deletion, hydrogen addition, and charge calculation. 
Solvent deletion is used so that DOCK software can explore the structure volume. 
Solvents such as water, as well as cofactor and ions are removed. Hydrogen atoms are 
added to the receptor structure to study different ligand interactions. The file is saved as 
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5coxrec_charged.mol2 and is shown in Figure 12. Hydrogen atoms are deleted from the 
file for molecular surface generation and the file is saved as 5coxrec_noH.pdb. 
Figure 12. The structure of 5coxrec_charged. 
6.5.3 Generating Spheres for the Target 
As a prerequisite for generating spheres in the target structure, the molecular 
surface of the target is generated using the dot molecular surface (dms) program. The 
input for the dms program is 5coxrec_noH.pdb. The output file is saved as 
5coxcutto50_more.ms and is shown in Figure 13 in the pdb format. 
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Figure 13. Molecular surface of the target (5coxcutto50_more.ms). 
To generate spheres over the molecular surface of the target, a program called 
sphgen is used. A file called INSPH is generated in the format shown in File 1. The file 
contains 5coxcutto50_more.ms, parameters, and an output file name (5coxrec.sph). 
File 1. The input file INSPH for sphere generation. 
5 c o x c u t t o 5 0 more.ms 
R 
X 
0 .0 
4 . 0 
1.4 
5 c o x r e c . s p h 
(sphere outside of surface) 
(subset of surface points) 
(prevents generation of large spheres 
with close surface contacts) 
(maximum sphere radius in Angstroms) 
(minimum sphere radius in Angstroms) 
(output file) 
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The command "sphgen" is run in the same folder that contains the INSPH file. 
Two output files are generated of which one is the 5coxrec.sph, which contains spheres in 
clusters. The output file generated has 49 clusters for the target molecule. The second 
output file is called the OUTSPH and contains calculation information. The 5coxrec.sph 
file is converted into pdb file format for viewing. File 2 shows the output file OUTSPH, 
and File 3 shows a partial file of 5coxrec.sph. 
File 2. The OUTSPH file. 
density type = X 
reading 5coxcutto50 more.ms 
type R 
# of atoms = 2 635 
# of surf pts = 9 2 3 7 8 
finding spheres for 5coxcutt 
dotlim = 0.000 
radmax = 4.000 
Minimum radius of acceptable s 
1.39999998 
output to 5coxrec.sph 
clustering is complete 4 9 
o50_ more.ms 
pheres? 
clusters 
File 3 is a partial list containing the cluster number and the number of spheres in 
that particular cluster. The first cluster is usually the largest cluster and is ranked 
according to the number of spheres in it. In File 3, the cluster number is one and has 314 
spheres in it. Figure 14 shows all the 49 clusters on the receptor structure in pdb format. 
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File 3. The 5coxrec.sph file with co-ordinates of spheres in clusters (a partial file). 
DOCK 3 .5 receptor spheres 
cluster 1 
I 
2 
6 
8 
11 
12 
13 
16 
28 
31 
32 
33 
34 
38 
43 
45 
46 
49 
50 
52 
56 
57 
58 
59 
60 
33.86127 
37.012S3 
38.22809 
37.48247 
32.10894 
31.46670 
34.59720 
31.10007 
32.10211 
31.37568 
32.19233 
29.84737 
31.09390 
29.60381 
31.71706 
29.81698 
31.76289 
29.05761 
29.25646 
29.02018 
28.82901 
27.41262 
27.61276 
30.15703 
32.97385 
number of 
5.24224 
6.03600 
10.20790 
10.. 76998 
9.69918 
8.01977 
10.21953 
9.94951 
6.51510 
7.53117 
7.88500 
7.92419 
10.21620 
-2.62915 
5.35851 
7.38218 
5.66931 
5.99802 
5.99636 
-3.41387 
6.30148 
3.52551 
3.92113 
5.77092 
3.12507 
spheres in 
-20.35150 
-17.87776 
-14.99500 
-13.64997 
-8.68469 
-7.57835 
-9.25875 
-10.27780 
-4.09244 
-3.17091 
-4.49252 
-2.58200 
-8.27045 
-2.16924 
-4.30791 
0.14289 
-4.19217 
0.99937 
1.38381 
-1.70898 
-0.89333 
4.01783 
4.48495 
5.98702 
7.13479 
cluster 
2.536 
2.555 
3.544 
3.008 
2.682 
1.628 
2.828 
1.955 
2.211 
2.509 
2.557 
2.189 
2.173 
2.443 
1.436 
2.786 
1 • 628 
2.243 
2.247 
3.030 
1.758 
2.298 
2.219 
2.106 
1.535 
* 314 
126 0 
121 0 
696 0 
694 0 
846 0 
32 0 
684 0 
857 0 
46 0 
45 0. 
841 0 
834 0 
846 0 
202 0 
29 0 
2054 0 
29 0 
2083 0 
2083 0 
202 0 
2054 0 
2083 0 
2083 0 
2082 0 
197 0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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Figure 14. The 5coxrec.sph file in pdb format. 
The 5coxrec.sph file was edited by splitting into 49 different cluster files. Then 
the cluster files were merged with the modified receptor file (5coxrec_noH.pdb) 
individually. The VEGA ZZ program was used to check if the spheres in the cluster were 
resting on the active site. It was found that the spheres in 5th cluster file matched with 
the active site of the receptor. The fifth cluster file is shown in File 4. 
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Figure 15. Green spheres filling up the active site of the target structure. 
This step demands a lot of visual inspection and time. If a different cluster file is 
chosen, it leads to a different output during the final docking step, sometimes resulting in 
an error message during docking. Previous studies have shown that the active site 
surrounded by tyrosine385, tryptophan 387, phenylalanine 518, tyrosine 248, leucine 
352, arginine 120, glutamic acid 524, tyrosine 355, valine 523, and phenylalanine 518 
residues. Based on this information, the residues were marked in white using the VEGA 
ZZ program and it was determined if the spheres were resting on the active site. 
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The exact cluster file will be given to the students after explaining the procedure 
for cluster selection. From the students' point of view, this will help them save time and 
avoid errors in cluster selection. 
6.5.4 Scoring Grids for the Target 
The purpose of this step is to generate energy scoring grids for the target 
structure. Prior to grid generation a box is constructed around the active site. The box 
specifies the location and size of the grid to be calculated. To create a box around the 
active site, a program called Show Box is used. The input file 5coxbox.in contains 
default parameters, the cluster file name, and the output file name. Figure 16 shows the 
output file 5_5coxrec_box.pdb. 
Figure 16. Box enclosing the active site of target and input file. 
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To generate the scoring grid, a program called Grid is used. This program 
calculates the force field scores that are approximate molecular mechanics interaction 
energies, comprised of sum of van der Waals and electrostatic interactions between the 
ligand and the receptor for the site enclosed by the grid box. The output from the 
calculation is stored as a scoring grid. The ligand-receptor binding energy is the sum of 
van der Waals attractive, van der Waals dispersive, and columbic electrostatic energies. 
E =
 S X \~J~~J+332~k:.) Equation 2 
i=\ j=\ rij rtj Ur'J 
E is the intermolecular interaction energy in Kcal/mol 
i and j are the ligand and the receptor atoms 
a and b are the van der Waals repulsive and attractive exponents 
Aij and Bij are the van der Waals repulsion and attraction parameters 
r ij is the distance between atoms i and j 
qi and qj is the point charges on the ligand i and receptor j atoms 
D is the dielectric function 
332 is the factor to convert electrostatic energy to kcal/mol 
The input file 5coxgrid.in is created, consisting of the target file, box file and vdw 
definition file along with the default parameters (obtained from demo version of DOCK). 
File 5 is the input file for the grid program. 
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File 5. The input file 5coxgrid.in for grid program. 
compute grids 
grid spacing 
output molecule 
contact score 
energy score 
energy cutoff distance 
atom model 
attractive exponent 
repulsive exponent 
distance dielectric 
dielectric factor 
bump filter 
bump overlap 
receptor file 
box file 
vdw definition file 
score grid prefix 
yes 
0.3 
no 
no 
yes 
9999 
a 
6 
12 
yes 
4 
yes 
0.75 
5coxrec charged.mol2 
5 5coxrec box.pdb 
vdw_AMBER_parm99.defn 
grid 
The command grid -i 5coxgrid.in is run. Grid generates two binary files, namely 
grid.bmp and grid.nrg. The grid.bmp file is a filter to remove ligand atoms that overlap 
on the target atoms during docking. The grid.nrg contains scoring grid information. 
For the ligand molecule, the structure file in the mol file format is obtained from 
KEGG Ligand Database and is opened and saved as HgandA.mol2 in VEGA ZZ. Using 
VEGA ZZ hydrogen atoms are added to complete the valency; charges are calculated for 
the ligand and are saved as ligandAcharged.mol2. The structures of ligands are given to 
the students and ligands' name remains unknown. The chemical names of the ligands are 
listed below. Figure 17 shows the chemical structures of the ligands in study. 
a. Ligand A = Acetyl salicylic acid 
b. Ligand B =Rofecoxib 
c. Ligand C = Celecoxib 
d. Ligand D = SC-558 (l-Phenylsulfonamide-3-trifluoromethyl-5-
parabromophenylpyrazole) 
e. Ligand E=Fucoxanthin 
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ligmdA 
O r S - 0 
LigtndD 
LigtndE 
Figure 17. The chemical structures of Ligand A, B, C, D, and E. 
Figure 18 is the structure of sample ligand acetyl salicylic acid followed by Figure 
19 showing the ligand with hydrogen atoms added to it. 
Figure 18. The structure of Ligand A (acetyl salicylic acid). 
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Figure 19. Hydrogen atoms are added to the Ligand A. 
6.5.5 Docking the Target and Ligand 
The purpose of this step is to bind the ligand to the target at the site chosen (active 
site) in the best orientation possible. The files ligandAcharged.mol2, cluster file 
(5cox_selected spheres.sph), and the grid file (grid.nrg) were included in the input file 
called 5coxanchor_and_grow.in. The default parameters from the input file of the demo 
version of DOCK were also added. The input file 5coxanchor_and grow.in is shown in 
File 6. 
51 
File 6. The input file 5coxanchor_and_grow.in. for Ligand A. 
ligand_atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use_internal_energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid_score_vdw_scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
minimize anchor 
minimize flexible growth 
use_advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
ligandAcharged.mol2 
flex 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
600 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
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simplex tors step 
simplex anchor max iterations 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize_pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
10.0 
500 
500 
no 
no 
0 
all 
vdw_AMBER_parm99.defn 
flex.defn 
flex drive.tbl 
With the help of File 6 (5coxanchor_and_grow.in), the final stage of docking is 
performed. Using the Cygwin window, DOCK is run using the command "dock -i dock, 
in -i dock, out", dock, in is the input file (5coxanchor_and grow, in) and dock, out is 
the output file. DOCK uses all the parameters from the input file for docking and if some 
data is not available it will be requested from the user. The above default parameters 
could be changed to experiment with the software. The output result is shown in File 7. 
At the end of the file is the lowest binding energy score of the best conformation for the 
ligand. The ligand docked into the receptor site is also shown in Figure 20. 
53 
File 7. The output file LigandA.docked.out. 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score_molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
ligandAcharged.mol2 
flex 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
5coxselectedspheres.sph 
600 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
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Grid Score Parameters 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
Simplex Minimization Parameters 
minimize ligand 
minimize anchor 
minimize flexible growth 
use advanced simplex_parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max iterations 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize_pose 
simplex random_seed 
Atom Typing Parameters 
atom model 
vdw defn file 
vdw_AMBER parm99.defn 
flex defn file 
flex.defn 
flex drive file 
flex drive.tbl 
Initializing Library File Routines... 
Initializing Orienting Routines... 
Initializing Conformer Generator Routines... 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
Molecule: ligandAcharged 
Elapsed time: 663 seconds 
Anchors: 1 
Orientations: 600 
Conformations: 83 
Grid Score: -38.733078 
vdw: -28.639036 
es: -10.094044 
1 Molecules Processed 
Total elapsed time: 664 seconds 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
500 
no 
no 
0 
all 
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The receptor structure shown in Figure 20 is shown in green and the docked 
ligand is shown in purple using UCSF Chimera. It is to be noted that DOCK outputs only 
the best oriented ligand in mol2.format. The receptor structure file was merged with the 
oriented ligand using the VEGA ZZ program to view the complete output. 
Figure 20. Ligand A docked into red receptor structure in flexible docking. 
The results presented in File 7 and Figure 20 is for flexible docking. Another 
form of docking is called rigid docking in which the receptor and ligand are assumed to 
be rigid structures and do not change spatially during docking process. The input file for 
rigid docking is given in File 8. The command for rigid docking is "dock6 - i rigid.in." 
and DOCK outputs two files rigid.out shown in File 9 and rigid_scored.mol2 shown in 
Figure 21 generated from UCSF Chimera. 
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File 8. The input file for rigid docking 5coxrigid.in. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible_ligand 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid score vdw_scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot_step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
ligandAcharged.mol2 
rigid 
no 
no 
5coxselectedspheres. 
vdw AMBER parm99 
flex 
no 
no 
no 
no 
no 
1 
yes 
yes 
sph 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
all 
defn 
defn 
flex drive.tbl 
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Figure 21. Rigid docking of Ligand A in receptor structure. 
File 9. The output file for rigid docking. 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
• ~ 
aspirincharged.mol2 
rigid 
no 
no 
no 
no 
no 
no 
no 
1 
58 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site_file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score_primary 
contact score secondary 
Grid Score Parameters 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
grid 
Simplex Minimization Parameters 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
Atom Typing Parameters 
atom model 
vdw defn file 
flex defn file 
flex drive file 
Initializing Library File Routines... 
Initializing Orienting Routines... 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
yes 
yes 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
all 
vdw_AMBER_parm99.defn 
flex_ 
flex.defn 
drive.tbl 
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Molecule: l igandAcharged 
E lapsed t i m e : 69 seconds 
Anchors : 1 
O r i e n t a t i o n s : 
Conformat ions : 
Grid S c o r e : 
vdw: 
e s : 
1 Molecules P roces sed 
T o t a l e l a p s e d t i m e : 
1000 
1000 
-36.690540 
-28.418787 
-8 .271753 
69 seconds 
The results for the other ligands are presented in Appendix A. The energy scores 
have been tabulated in Table 1 for rigid and flexible docking. The more negative the 
score, the higher the binding affinity. The computer output of these numbers have been 
expressed to three significant figures in light of accuracy of the data, the calculations are 
based. Figure 22 and Figure 23 shows an ensemble of all the ligands in various colors 
docked in the receptor binding site. 
Table 1. The binding scores of the docked ligands. 
Ligand 
Ligand A(acetyl 
salicylic acid) 
Ligand B(rofecoxib) 
Ligand C(celecoxib) 
Ligand D(SC-558) 
Ligand E(fucoxanthin) 
Grid score for flexible 
docking Kcal/mol 
-38.7 
-40.3 
-34.5 
-40.7 
Error: Could not complete 
growth. Confirm grid box 
is large enough to contain 
ligand 
Grid score for rigid 
docking 
Kcal/mol 
-36.6 
-35.4 
-14.5 
13.4 
Error: Conformation 
could not be scored by 
DOCK. Conformation 
not completely within 
grid box. 
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Figure 22. Three ligands A, B, C, and D bound to receptor in flexible docking. 
Figure 23. Four ligands A, B, C, and D bound to the receptor in rigid docking. 
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The results from Table 1 for flexible docking show that Ligand D (SC-558) and 
Ligand B (rofecoxib) have the lowest binding scores -40.7 and -40.3 kcal/mol, indicating 
high binding affinity. This is followed by Ligand A (acetyl salicylic acid) with a binding 
score of-38.7 kcal/mol. Ligand C (celecoxib), when compared with the other ligands has 
the least binding score (-34.5 kcal/mol) exhibiting less binding interactions inspite of the 
fact that like Ligands B and D, it belongs to the coxib group. Ligand B, Ligand C and 
Ligand D belong to the diaryl heterocyclic group that has a central pyrazole ring and a 
sulphonamide substituent attached to the aryl ring. The sulphonamide group of ligands 
B, C, and D binds into the side pocket of the COX-2 active site as shown in Figure 23. 
Ligand E could not be docked because the DOCK software gave an error message stating 
that the grid box enclosing the active site was too small to fit the ligand. Increasing the 
gridbox had no effect on the result. Based on the flexible docking results, all the ligands 
except Ligand E can be considered as potential lead candidates. 
Rigid docking is considered a basic mode of docking because the receptor and the 
ligand are assumed to be non-flexible. Ligand A (acetyl salicylic acid: -36.6 kcal /mol) 
has the lowest energy score resulting in high binding affinity and is closely followed by 
Ligand B (-35.400 kcal/mol). Ligand C (celecoxib) has a lowest binding score of-14.5 
kcal mol displaying least binding affinity. Ligand D (SC-558) exhibited a positive score 
resulting in no binding affinity. The Ligands B, C, and D belong to the same family (the 
coxib group), yet Ligands D and C display poor binding affinity-this could be due to an 
additional functional group. Ligand E (fucoxanthin) could not be docked because the 
conformation was too large to fit inside the grid box. This clearly shows that Ligand E is 
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too large a ligand to fit inside the COX-2 active site. Based on rigid docking results, 
Ligand A and Ligand B alone can be considered good lead compounds. 
6.6 Ligand Evaluation 
Five ligands were docked into the receptor structure individually using the DOCK 
software. The ligands are evaluated based on Lipinski's Rule of Five which states that 
poor absorption or permeation is more likely when: 
> There are more than five H-bond donors. 
> The molecular weight is over 500. 
> The logP (partition coefficient) is over 5. 
> The sums of N's and O's are over 10. 
Based on Veber's paper, the number of rotatable bonds should be less than 10 for 
oral bioavailability. Based on the five characteristics, the ligands are tabulated in Table 2 
based on values obtained from Pubmed database. 
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Table 2. Ligand with "Lipinski Rule of Five" characteristics. 
Ligand 
Ligand A(acetyl 
salicylic acid) 
Ligand B 
(rofecoxib) 
Ligand C 
(celecoxib) 
Ligand D (SC-
558) 
Ligand 
E(fucoxanthin) 
LogP 
Partition 
coefficient 
1.4 
3.2 
3.9 
4.2 
7.9 
OH+NH 
H-bond 
donors 
1 
0 
1 
1 
2 
MolWt 
g/mol 
180.16 
314.357 
381.373 
446.243 
658.906 
N+O 
H-bond 
acceptors 
4 
4 
8 
8 
6 
Rotatable 
bonds 
3 
3 
3 
3 
12 
Alert 1: 
good; 
0: poor 
1 
1 
1 
1 
0 
Examination of Table 2 shows that ligands A-D obey the Rule of 5 to a greater or 
lesser extent. Ligand E does not obey the criteria and can be considered a poor ligand. 
Ligand D is at the borderline; all the other ligands are well within the limit. It is known 
that permeability decreases with high molecular weight, resulting in less bioabsorption 
[35]. Log P is the partition coefficient; this parameter is found to be directly proportional 
to the molecular weight. As the molecular weight increases, the log P values become 
larger, indicating lower permeability shown in Figure 24. 
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658.906 
8 9 
Figure 24. Graph showing LogP vs. molecular weight. 
Comparing the results obtained from DOCK and those of Lipinski's Rule of Five, 
Ligand A is the smallest compound, and it fits into the active site like a ball in a glove. 
The enclosed binding site allows enough space for Ligand A to move inside the site, 
thereby displaying a low energy score. The energy score from rigid docking is similar to 
that of flexible docking (-38.733 kcal/mol). Also, Ligand A penetrates deep into the 
hydrophobic pocket showing that it can also bind to the COX-1 active site in a similar 
fashion (49). This shows that it is a non- selective inhibitor and that there is a possibility 
that it will inhibit both COX-1 and COX-2 when it enters the human body. Our aim is to 
inhibit only COX-2, so Ligand A does not serve the purpose of a good lead in spite of its 
good binding score. Ligand B (rofecoxib) binds to the side pocket of the COX-2 active 
site in rigid and flexible docking. The side pocket feature is unique only to COX-2 and 
there is less probability that Ligand B would bind to COX-1 when it enters in the human 
system. The same argument can be applied to Ligands B, C, and D (coxib group) as they 
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all bound to the side pocket of COX-2 and showed high binding affinity. They can be 
good lead compounds as well as selective inhibitors for COX-2. Ligand D has a bromine 
atom attached to one of the rings; it might be eliminated during the preclinical testing 
phase due to the toxic properties of the halogen. The ligand-enzyme complexes for 
Ligands B and C (available from literature) are compared with the results obtained in this 
study-this is presented in Appendix A. 
The binding energies of these ligands need to be determined using experimental 
methods and compared with the predicted results. If the RMSD values of the predicted 
and the experimental values are similar, then the ligand could be further studied for 
preclinical testing. 
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CHAPTER SEVEN 
CONCLUSIONS 
The process of structure-based drug design was studied. The drug design 
concepts were applied to a case study that finds the top scoring ligand using COX-2 as a 
drug target. The COX-2 enzyme is an excellent drug target for osteoarthritis. The UCSF 
DOCK program was used to predict the binding energies and the VEGA ZZ program to 
visualize the results. Five known ligands were treated as novel compounds for the drug 
design study. It was found that Ligand B (rofecoxib), Ligand C (celecoxib), and Ligand 
D (SC-558) were good inhibitors of COX-2 based on docked results. Based on 
Lipinski's Rule of Five, it was found that the permeation of the ligand depends on the 
molecular weight and the partition coefficient. To prove the real potential of the ligands 
used in this case study, they need to be tested experimentally. 
There is always a possibility that the predicted values may not be equal to those of 
the experimental values. It is probable that the lower scoring compounds might perform 
better under experimental conditions. Apart from structural details, factors such as 
bioabsorption, chemical stability, and production costs also play an important role in 
determining the lead drug. 
67 
REFERENCES 
1. The National Institute of General Medical Sciences (2004) NIGMS-Supported Structure-
based Drug Design Saves Lives [online] Available at http://www.nigms.nih. 
gov/news/facts/structuredrugs.html (accessed September 24, 2004). 
2. University of Waterloo (2004) Drug discovery in the bioinformatics age [online] 
Available at http://monod.uwaterloo.ca/cs798/proteomics.pdf (accessed September 24, 
2004). 
3. The Wellcome Trust (2004) An overview of drug development [online] Available at 
http://www.wellcome.ac.uk/en/genome/tacklingdisease/hg09b005 .html_(accessed 
September 24,2004). 
4. The National Institute of General Medical Sciences (2004) NIGMS-Supported Structure-
based Drug Design Saves Lives [online] Available at 
http://publications.nigms.nih.gov/basicresearch/ (accessed September 24,2004). 
5. Graham H. Coombs, Daniel E. Goldberg, Michael Klemba, Colin Berry, John Kay and 
Jeremy C. Mottram, " Aspartic proteases of Plasmodium falciparum and other parasitic 
protozoa as drug targets, " Trends in Parasitology 17(11), 2001. 
6. R. Banerjee, S.E. Francis and D.E. Goldberg, ''''Food vacuole plasmepsins are processed 
at a conserved site by an acidic convertase activity in Plasmodium falciparum, "Mol. 
Biochem. Parasitol. 129,157-165 (2003). 
7. Kishore R. Sakharkar, Meena K. Sakharkar and Vincent T.K. Chow, " A novel genomics 
approach for the identification of drug targets in pathogens, with special reference to 
Pseudomonas aeruginosa, " in silico Biology, 4, 0028 (2004). 
8. Pearl L.H, Taylor W.R, "A structural model for the retroviral proteases, " Nature 329, 
351-354(1987). 
9. Navia M.A, Fitzgerald P.M, McKeever B.M, Leu C.T, Heimbach J.C,"Three-
dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1, " 
Nature 337, 615-20 (1989). 
10. Rational drug design approach to synthesizing HIV-Protease inhibitors (Online) 
Available at http://biocheml 18.stanford.edu/Projects/1999/ding.pdf (accessed June 
2006). 
11. National Cancer Institute, Molecular crystallography laboratory [online] Available at 
http://xpdb.nist.gov/hivsdb/gallery.html (accessed October 14, 2004). 
68 
12. Akihiko Kuniyasu, " Identification of the Ligand Binding Sites and Novel Drug Target 
Molecules by Photoaffinity Labeling, " 123(8), 673-679 (2003). 
13. A. Filikov, V. Mohan, T. Vickers, R. Griffey, P. Cook, R. Abagyan and T. James, 
"Identification ofligandsfor RNA targets via structure-based virtual screening: HIV-1 
TAR, " J.Comput.Aided Mol Des. 6, 593-610 (2000). 
14. M. Hendlich, F. Rippmann and G. Barnickel, "LIGSITE: automatic and efficient 
detection of potential small-molecule binding sites in proteins, " J.Mol.Graph.Model 15, 
359-363 (1997). 
15. K. P.Peters, J. Fauck and C. Frommel, "The automatic search for ligand binding sites in 
proteins of known three-dimensional structure using only geometric criteria, " J.Mol. 
Biol. 256,201-213(1996). 
16. G.P. Brady, Jr and P.F. Stouten, " Fast prediction and visualization of protein binding 
pockets with PASS, " J.Comput.Aided Mol.Des. 14, 383-^01 (2000). 
17. LIGSITE: M. Hendlich, F. Rippman and G. Barnickel, SITE2SPHERES [online] 
Available at http://www.daylight.com/meetings/mugO l/Dixon/ligsitedescr.html_(accessed 
October 24,2004). 
18. H. Boehm, "The computer program, LUDI: a new method for the de novo design of 
enzyme inhibitors," J.Comput.Aided Mol.Des. 6, 61-78 (1992). 
19. H. Boehm, "Towards the automatic design of synthetically accessible protein ligands: 
Peptides, amides andpeptidomimetics, " J.Comput.Aided Mol.Des. 10, 265-272 (1996). 
20. Gillet P. Johnson, P. Mata, S. Sike and P. Williams, "Sprout: a program for structure 
generation."}.CompvX.A\&QdiMol. Des. 7,127-153(1993). 
21. M. Eisen, D. Wiley, M. Karplus and R. Hubbard, "Hook: a program for finding novel 
molecular architectures that satisfy the chemical andsteric requirements of 
macromolecule binding sites", Proteins 19,199-221 (1994). 
22. R. Bohacek and C. McMartin, "Multiple highly diverse structues complementary to 
enzyme binding sites: Results of extensive application of a de novo design method 
incorporating combinatorial growth", J. Am. Chem. Soc. 116, 5560-5571 (1994). 
23. P. Goodford, "A computational procedure for determining energetically favorable 
binding sites on biologically important macromolecules ", J. Med. Chem. 28. 849-857 
(1985). 
69 
24. P. Bartlett, G. Shea, S. Telfer and S. Waterman, "Caveat: a program to facilitate the 
structure-derived design of biologically active molecules", Molecular Recognition: 
Chemical and Biological Problems, Royal Society of Cambridge, Cambridge 182-196 
(1989). 
25. Y. Nishibata and A. Itai, "Confirmation of usefulness of a structure construction program 
based on three-dimensional receptor structure for rational lead generation ", J. Med. 
Chem. 36,2921-2928 (1993). 
26. P. A. Kollman "Free Energy Calculations: Applications to Chemical and Biochemical 
Phenomena:' Chem. Rev. 93,2395-2417 (1993). 
27. R.L. DesJarlais, G.L. Seibel, I.D. Kuntz, P. S. Furth, J.C. Alvarez, P.R Ortiz de 
Montellano, D.L. DeCamp, L.M. Babe, and C.S Craik, "Structure-based design of 
nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease, " Proc 
Natl Acad Sci U S A . 87, 6644-6648 (1990). 
28. D. Lorber and B. Shoichet, "Flexible ligand docking using conformational ensembles. " 
Protein Sci. 7,938-950(1998). 
29. T.Ewing, S.Makino, G. Skillman and I. Kuntz, "Dock 4. 0: search strategies for 
automated molecular docking of flexible molecule databases, " J. Comput. Aided Mol. 
Des. 15,411-428(2001). 
30. C. Lipinski, F. Lombardo, B.Dominy and P. Feeney, "Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development 
settings," Adv. DrugDeliv. Rev. 23,3-4(1997). 
31. D. Veber, S. Johnson, H. Cheng, B, Smith, K.Ward and K. Kopple, "Molecular 
properties that influence the oral bioavailability of drug candidates, " J. Med. Chem. 
45,2615-2623(2002). 
32. Sokoloff, Leon. The biology of degenerative joint disease (Chicago, University of 
Chicago Press [1969] 
33. Giuseppe Ermondia, Giulia Carona, Raelene Lawrenceb, and Dario Longo, "Docking 
studies on NSAID/COX-2 isozyme complexes using Contact statistics analysis, " Journal 
of Computer-Aided Molecular Design. 18,683-696 (2004). 
34. Kurumbail R.G, Stevens A.M, Gierse J.K, McDonald J.J, Stegeman R.A, Pak J.Y, 
Gildehaus D, Miyashiro J.M, Penning T.D, Seibert K, Isakson P.C,and Stallings W.C, " 
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory 
agents, " Nature. 384 (6610), 644-8 (1996). 
70 
35. The Official UCSF DOCK Web-site [online] Author Therese Lang Available at 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/sphere_generation/generating_spheres.ht 
m. 
36. The Official UCSF DOCK Web-site [online] Author Therese Lang et al. Available at 
http://dock.compbio.ucsf.edu/DOCK_6/dock6_manual.htm 
37. The Official UCSF DOCK Web-site [online] Author 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/grid_generation/generating_grid.html 
38. The Official UCSF DOCK Web-site [online] Author Therese Lang Available at 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/struct_prep/prepping_molecules.htm 
39. Bio computing and drug design [online] Available at http://www. techfak. uni-bielefeld. 
de/bcd/ForAll/Introd/drugdesign. html (accessed October 14,2004). 
40. Health and Medical Information produced by Doctors [online] Available at 
http://www. medicinenet.com/rheumatoid%20arthritis/article.htm (accessed October 14, 
2004). 
41. M. Huynen, Y. Diaz-Lazcoz, and P. Bork, "Differential genome display. Trends 
Genet," 13, 389-390 (1997). 
42. Amy C. Anderson, "The Process of Structure-Based Drug Design, " Chemistry & 
Biology, 10,787-797(2003). 
43. UCSF DOCK dock-fans ~ Molecular docking and virtual screening discussion group 
[online] Available at http://blur.compbio.ucsf.edu/mailman/listinfo/dock-fans. 
71 
APPENDIX A 
LIGAND AND TARGET STRUCTURE INFORMATION AND DOCKING RESULTS 
1. Ligand A 
The information for Ligand A was obtained from KEGG Ligand Database. The 
mol file is saved in mol2 format and visualized in VEGA. The information is shown in 
Figure 1 and mol file for Ligand A is shown in File 1. 
KIU#fc COMPOUND: C01405 
Entry 
Home 
Formula 
Mass 
Structure 
Remark. 
Reaction 
Enzyme 
Other DBs 
LinkDB 
KCF data 
C01405 Compound 
Aspirin; 
Acetylsalicylic acid; 
2-Acetoxybenzenecarboxylic acid; 
Acetylsalicylate 
:9H804 
180.0423 
C01405 
^MojMRtej
 vKCFfik»j .DBsearchj 
Same as: D00109 
R02942 
L4.99.1 (I) 3.1.1.55 
CAS: 50-7S-2 
PubChem: 4594 
ChEBI: 153€5 
3DMET: B00284 
All DBsj 
Show 
Figure 1. Information for Ligand A in the KEGG Ligand Database. 
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2. Ligand B 
The information for Ligand B was obtained from KEGG Ligand database. The 
mol file was copied and saved in mo!2 format and visualized in VEGA. The information 
and mol file for Ligand B is shown in Figure 2 and File 2 respectively. 
*[cc COMPOUND: C07590 
-H-P.J 
Entry 
Name 
Fornula 
Mass 
Structure 
Remark 
Other DBs 
LinkDB 
KCF data 
C07590 Compound 
Rafecoxib 
C17H1404S 
314,0613 
0 [| 1 
^ j T p 
r ^ ^ r u 
u ° 
C07590 
^ Mai fite j
 VKCF fite j J3B search j 
Same as: D3056S 
CkS: 162011-90-7 
PubCfaem: 9792 
ChEBI: SS37 
All DBs j 
^ Show j 
Figure 2. Information of Ligand B in the KEGG Ligand Database. 
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File 2. Mol file for Ligand B exported from KEGG Ligand Database. 
22 24 0 0 0 0 0 0 0 0999 V2000 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 2 
2 3 
3 4 
4 5 
1 5 
5 6 
7 8 
8 9 
9 10 
10 11 
11 12 
7 12 
11 4 
13 14 
14 15 
15 16 
16 17 
17 18 
13 18 
16 3 
13 19 
19 20 
19 21 
19 22 
: END 
1 
1 
2 
1 
1 
2 
2 
1 
2 
1 
2 
1 
1 
2 
1 
2 
1 
2 
1 
1 
1 
2 
2 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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29.9147 -19.5829 
29.0770 -18.4195 
27.7739 -18.8384 
27.7739 -20.2810 
29.0770 -20.6999 
29.5424 -22.0030 
24.1439 -20.9791 
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Figure 3. Ligand B chemical structure. 
Figure 4. Hydrogen atoms are added to Ligand B. 
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Hydrogen atoms are added to the ligand file; charges are calculated and saved as 
HgandBcharged.mol2. The total charge is 0.0 calculated using Gasteiger charges in the 
VEGA ZZ program. 
For flexible docking the files ligandBcharged.mol2, cluster file (5cox_seleeted 
spheres.sph), and the grid file (grid, nrg) was incorporated into the input file called 
5coxanchor_and_grow. in. The default parameters from input file of demo version of 
DOCK were also added. The input file 5coxanchor_and grow, in is shown in File 3. 
File 3. Input file 5cpxanchor__and _grow.in. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule .''•.'•••• 
calculate rmsd 
use rmsd reference mol 
rank_ligands 
max ranked ligands 
scored conformer output override 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max_orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use_internal energy 
internal energy.att exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
bump filter 
score molecules 
contact score primary 
contact score secondary 
ligandBcharged.mol2 
flex 
no 
no 
no 
no 
no 
yes 
1 
yes 
3 
no 
yes 
yes 
600 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
77 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score_es scale 
grid score grid prefix 
minimize ligand 
minimize anchor 
minimize flexible growth 
use advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max iterations 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize_pose 
simplex random seed 
atom model 
vdw defn file 
vdw AMBER parm99.defn 
flex defn file 
flex drive file 
flex_drive.tbl 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
500 
no 
no 
0 
all 
flex.defn 
File 4. The output file ligandBdocked.out. 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
ligandBcharged.mol2 
ligand outfile prefix 
limit max ligands 
read_mol_solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
use rmsd reference mol 
rank ligands 
max ranked ligands 
scored conformer output override 
Orient Ligand Parameters 
use rmsd reference mol 
rank ligands 
max ranked ligands 
scored conformer output override 
flex 
no 
no 
no 
no 
no 
yes 
1 
yes 
3 
no 
1 
yes 
3 
no 
78 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
Grid Score Parameters 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
Simplex Minimization Parameters 
minimize ligand 
minimize anchor 
minimize flexible growth 
use advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max iterations 
simplex grow max iterations 
simplex final min_add internal 
simplex secondary minimize pose 
yes 
yes 
600 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
500 
no 
no 
79 
simplex_random_seed 
Atom Typing Parameters 
atom_model 
vdw_de fn_f i1e 
vdw_AMBER_parm99.defn 
flex_defn_file 
flex drive file 
all 
flex.defn 
flex drive.tbl 
Initializing Library File Routines... 
Initializing Orienting Routines... 
Initializing Conformer Generator Routines. 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
Molecule: ligandB 
Elapsed time: 
Anchors: 
Orientations: 
Conformations: 
Grid Score: 
vdw: 
es: 
460 
1 
seconds 
600 
89 
-40.356724 
-41.383575 
1.026853 
1 Molecules Processed 
Total elapsed time: 460 seconds 
Figure 5. Ligand B in green docked in the red receptor structure COX-2. 
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File 5. Input file for rigid docking for Ligand B. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
use rmsd reference mol 
rank ligands 
max ranked ligands 
scored conformer output override 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
minimize ligand. 
simplex max iterations 
simplex max cycles 
simplex score_converge 
simplex cycle converge 
simplex trans_step 
simplex rot step 
simplex tors_step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
ligandBcharged 
rigid 
no 
no 
no 
no 
no 
yes 
1 
yes 
3 
no 
yes 
yes 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0:1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
all 
vdw AMBER parm99.defn 
flex.defn 
flex drive.tbl 
mol2 
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File 6. Output file for Ligand B in rigid docking. 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
use_rmsd reference mol 
rank ligands 
max ranked ligands 
scored conformer output_override 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score_molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
ligandBcharged.mol2 
rigid 
no 
no 
no 
no 
no 
yes 
1 
yes 
3 
no 
yes 
yes 
5coxselectedspheres.sph 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
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Grid Score Parameters 
g r i d score primary 
g r i d score secondary 
g r i d score vdw s c a l e 
g r i d score es s ca l e 
g r i d score g r i d p re f ix 
Simplex Minimization Parameters 
minimize l igand 
simplex max i t e r a t i o n s 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex t r a n s s t ep 
simplex ro t s t ep 
simplex t o r s s t ep 
simplex f i n a l min add i n t e r n a l 
simplex secondary minimize pose 
simplex random seed 
Atom Typing Parameters 
atom model 
vdw defn f i l e vdw 
f lex defn f i l e 
f l ex d r ive f i l e 
I n i t i a l i z i n g Library F i l e R o u t i n e s . . . 
I n i t i a l i z i n g Orient ing R o u t i n e s . . . 
I n i t i a l i z i n g Grid Score R o u t i n e s . . . 
Reading the energy g r i d from g r i d . n r g 
Molecule: ligandB 
E lapsed t i m e : 137 seconds 
Anchors : 1 
O r i e n t a t i o n s : 1000 
Conformat ions : 1000 
Grid Sco re : -35 .400383 
vdw: -36.430904 
e s : 1.030523 
1 Molecules Processed 
T o t a l e l a p s e d t i m e : 138 seconds 
yes 
yes 
1 
1 
gr id 
yes 
1000 
1 
0 . 1 
1.0 
1.0 
0 . 1 
10.0 
no 
no 
0 
a l l 
AMBER parm99.defn 
f l ex .de fn 
f lex d r i v e . t b l 
83 
Figure 6. Ligand B docked in white receptor structure COX-2 in rigid docking. 
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3. Ligand C 
The information for Ligand C was obtained from KEGG Ligand database. The 
mol file was saved in mol2 format and visualized in VEGA. The information and mol 
file for Ligand C is given in Figure 7 and File 5. 
\cc DRUG: D00567 Help 
Entry D00567 Drug 
Name Celecoxib (JAN/USAN/INN); 
Celebrex <TN} 
Formula :17H14F3N302S 
Mass 381.0759 
S t r u c t u r e 
Mol file j -JKCFfitej J3B searchj 
Target cyclooxygenase-2 (COX-2) inhibitor [HSA:5743J [EC:1.14.99.1] 
Iftetivity Anti-inflammatory and analgesic [cyclooxygenase-2 inhibitor] 
Remark Same as; C07589 
Therapeutic category: 1149 
Pathway PATH: map07112 1,2-Diphenyl substitution family 
Other DBs CAS: l€959Q-42-5 
PubChem: 7847633 
LinkDB Ail DBs , 
KCF d a t a Show J 
Figure 7. Information of Ligand C in the KEGG Ligand Database. 
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Figure 8. Ligand C with hydrogen atoms added. 
File 6. Input file 5coxanchor_and grow.in for LigandC. 
ligand atom file 
ligand outfile_prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
use rmsd reference_mol 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal energy 
internal energy att_exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
ligandCcharged.mol2 
flex 
no 
no 
no 
no 
no 
yes 
1 
no 
1 
yes 
yes 
5coxselectedspheres.sph 
600 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
87 
bump_filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid_score secondary 
grid_score vdw scale 
grid_score es scale 
grid score grid prefix 
minimize ligand 
minimize anchor 
minimize flexible growth 
use advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max iterations 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw_defn file 
flex_defn file 
flex_drive file 
vdw AMBER parm99 
flex 
defn 
defn 
flex drive 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
500 
no 
no 
0 
all 
tbl 
Figure 9. Ligand C in red receptor structure in flexible docking. 
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File 7. Output file for Ligand C in flexible docking. 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
ligand outfile_prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
use rmsd reference mol 
rank ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal_energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use_clash_overlap 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
ligandCcharged.mol2 
flex 
no 
no 
no 
no 
no 
yes 
1 
no 
1 
yes 
yes 
600 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
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Grid Score Parameters 
g r i d score primary 
g r i d score secondary 
g r i d score vdw sca l e 
g r i d score es s ca l e 
gr id_score g r id p r e f i x 
Simplex Minimization Parameters 
minimize l igand 
minimize anchor 
minimize f l e x i b l e growth 
use advanced simplex parameters 
simplex max cyc les 
simplex score converge 
simplex cycle converge 
simplex t r a n s s t ep 
simplex ro t s t ep 
simplex t o r s s t e p 
simplex anchor max i t e r a t i o n s 
simplex grow max i t e r a t i o n s 
s implex_f inal min add i n t e r n a l 
simplex secondary minimize pose 
simplex random seed 
Atom Typing Parameters 
atom model 
vdw defn f i l e 
f lex defn f i l e 
f lex d r ive f i l e 
f lex d r i v e . t b l 
I n i t i a l i z i n g Library F i l e R o u t i n e s . . . 
I n i t i a l i z i n g Or ien t ing R o u t i n e s . . . 
I n i t i a l i z i n g Conformer Generator R o u t i n e s . . . 
I n i t i a l i z i n g Grid Score R o u t i n e s . . . 
Reading the energy g r id from g r i d . n r g 
Molecule: l igandClcharged 
Elapsed t ime: 1523 seconds 
Anchors: 1 
Or ien ta t ions : 600 
Conformations: 75 
Grid Score: -34.592548 
vdw: -25.055355 
e s : -9.537194 
1 Molecules Processed 
Total elapsed t ime: 1523 seconds 
yes 
yes 
1 
1 
gr id 
yes 
yes 
yes 
no 
1 
0 . 1 
1.0 
1.0 
0 . 1 
10.0 
500 
500 
no 
no 
0 
a l l 
vdw AMBER parm99.defn 
f l ex .defn 
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File 8. Input file for Ligand C in rigid docking. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
ligandCcharged 
5coxsele 
vdw AMBER 
flex 
flex 
mc 
ri 
12 
gid 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
ctedspheres.sph 
parm99 
.defn 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
all 
.defn 
drive.tbl 
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File 9. Output file for Ligand C in rigid docking. 
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ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
Grid Score Parameters 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
Simplex Minimization Parameters 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
ligandCcharged.mol2 
rigid 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
5coxselectedspheres.sph 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
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simplex ro t s t ep 
simplex t o r s s t e p 
simplex f i n a l min add in t e 
simplex secondary minimize 
simplex random seed 
Atom Typing Parameters 
atom model 
vdw defn f i l e 
vdw_AMBER_parm9 9.defn 
f lex defn f i l e 
f lex d r ive f i l e 
I n i t i a l i z i n g Library F i l e 
rna l 
pose 
R o u t i n e s . . . 
I n i t i a l i z i n g Or ien t ing R o u t i n e s . . . 
I n i t i a l i z i n g Grid Score R o u t i n e s . . . 
Reading the energy g r i d from g r i d . n r g 
Molecule: l igandClcharged 
E lapsed t i m e : 158 
Anchors : 1 
O r i e n t a t i o n s : 
Conformat ions : 
Grid S c o r e : 
vdw: 
e s : 
1 Molecules P rocessed 
T o t a l e l a p s e d t i m e : 
seconds 
1000 
1000 
-14.554059 
-3 .643506 
-10 .910553 
158 seconds 
0.1 
10.0 
no 
no 
0 
a l l 
f lex .defn 
f lex d r i v e . t b l 
Figure 10. Ligand C in the receptor structure (rigid docking). 
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4. Ligand D 
The information for Ligand D was obtained from Protein Data Bank. The ligand 
that was docked into another structure of cyclooxygenase was used. The file 6COX.pdb 
was opened in VEGA ZZ program and the ligand SC-558 was isolated and saved as 
ligand D in mol2 format. 
Figure 11. The structure of Ligand D. 
Figure 12. The structure of Ligand D with hydrogens. 
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File 10. The input file for flexible docking of Ligand D. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
use rmsd reference mol 
rank ligands 
max ranked ligands 
scored conformer output override 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid,score grid prefix 
minimize ligand 
minimize anchor 
minimize_flexible_growth 
use advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max iterations 
s58charged.mol2 
flex 
no 
no 
yes 
yes 
no 
yes 
s58charged.mol2 
yes 
20 
no 
yes 
yes 
5coxselectedspheres.sph 
100 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
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simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
500 
no 
no 
0 
all 
vdw AMBER parm99.defn 
flex.defn 
flex drive.tbl 
File 1 l.The output file of the flexible docked Ligand D. 
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Molecule Library Parameters 
ligand atom file 
s58charged.mol2 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
min anchor size 
num_anchor orients_for growth 
number confs for next growth 
use internal energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use clash_overlap 
flex 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
500 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
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Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
Grid Score Parameters 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
Simplex Minimization Parameters 
minimize ligand 
minimize anchor 
minimize flexible growth 
use advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max itera tions 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
Atom Typing Parameters a 
vdw defn file 
flex defn file 
flex drive file 
flex drive.tbl 
Initializing Library Fil 
torn model 
e Routines.. . 
Initializing Orienting Routines... 
Initializing Conformer Generator Routines. 
Initializing Grid Score 
Reading the energy grid 
Molecule: s58charged 
Elapsed time: 4 94 
Anchors: 1 
Orientations: 
Conformations: 
Grid Score: 
vdw: 
es: 
1 Molecules Processed 
Total elapsed time: 
Routines... 
from grid.nrg 
seconds 
600 
46 
-40.702839 
-27.807253 
-12.895587 
4 94 seconds 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
500 
no 
no 
0 
all 
vdw AMBER parm99.defn 
flex.defn 
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Figure 13. Ligand D bound in red receptor structure in flexible docking. 
Figure 14. Comparison of 2 model structures COX-2(pink) from the demo module of 
UCSF Chimera vs. the model determined here for Ligand D SC-558(grey). 
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File 12. The input file for rigid docking of Ligand D. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
bump filter 
score molecules 
contact score primary 
contact score secondary-
grid score primary 
grid score secondary . . 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
flex drive.tbl 
s58charged .mol2 
rigid 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
5coxselectedspheres.sph 
1000 
vdw AMBER parm99 
fl 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
all 
.defn 
ax.defn 
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File 13. The output file for rigid docking of Ligand D. 
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ligand atom file 
s58charged.mol2 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank_ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
rigid 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
100 
Grid Score Parameters 
grid score_primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
Simplex Minimization Parameters 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
Atom Typing Parameters 
atom model 
all 
vdw defn file 
vdw AMBER_parm99.defn 
flex defn file 
flex.defn 
flex drive file 
flex drive.tbl 
Initializing Library File Routines... 
Initializing Orienting Routines... 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
Molecule: s58charged 
Elapsed time: 8 9 seconds 
Anchors: 1 
Orientations: 1000 
Conformations: 1000 
Grid Score: 13.429971 
vdw: 26.112669 
es: -12.682698 
1 Molecules Processed 
Total elapsed time: 8 9 seconds 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
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Figure 15. Ligand D docked in red receptor structure COX-2 in rigid docking. 
5. Ligand E 
The information for Ligand Ewas obtained from KEGG Ligand database. The 
mol file was saved in mol2 format and visualized in VEGA. The information and mol 
file for Ligand E is given in Figure 16 and File 5. 
Figure 16. Ligand E structure with hydrogens. 
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«\cc COMPOUND: C08596 
Entry 
Name 
Formula 
Mass 
Structure 
Other DBs 
LinkDB 
KCF data 
C0S596 Compound 
Fucox&nthin 
C42H5806 
65S.4233 
H,C CH, W> W, 
HOhAXN, 
A/ 
fY* 
0 
HCT—^*CHj ' a s 
C08596 
v Mol file j ', KCF fite j ,DB search] i Jmol j tKegprawi 
CAS: 3351-86-8 
PubChem: 10789 
ChEBI: 5186 
v All DBs J 
l Show j 
Figure 17. Information for Ligand E in the KEGG Ligand Database. 
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File 14. The mol file for Ligand E. 
ISISHOST03240423202D 1 
48 50 0 1 0 
-4. 
-4. 
-4. 
-5. 
-4. 
-5. 
-4. 
-5. 
-5. 
-4. 
-3. 
-5, 
-3. 
-3. 
-6. 
-2. 
-3. 
-2. 
-1. 
-1. 
-1. 
-1. 
-0. 
-0. 
0. 
0. 
1. 
0. 
1. 
2. 
2. 
3. 
2. 
3. 
3. 
4. 
3. 
4. 
4. 
4. 
4. 
3, 
3. 
4. 
5. 
5. 
6. 
5. 
.6414 
.6414 
,1931 
.1000 
.1931 
.1000 
,1931 
.5655 
.3690 
.8414 
.7345 
.5655 
.2828 
.7414 
.0000 
.8276 
.2897 
.3724 
.9172 
.4621 
.0069 
.4655 
.5517 
.0966 
.3552 
.8103 
.2621 
.8069 
.7207 
.1724 
.6276 
.0862 
.6241 
.5379 
.9897 
.4448 
.9897 
.9034 
.7069 
.1793 
.4448 
.8517 
.4793 
.9034 
.3621 
.8138 
.2655 
.8069 
-0.3483 
-0.8759 
-0.6103 
-0.0828 
-0.0828 
-1.1379 
-1.1379 
-0.3483 
0.3724 
0.3724 
-0.3448 
-0.8759 
-0.0793 
-0.8690 
-1.1345 
-0.3414 
0.4483 
-0.0759 
-0.3379 
-0.0724 
-0.3345 
0.4517 
-0.0724 
-0.3345 
-0.0690 
-0.3310 
-0.0655 
-0.8586 
-0.3276 
-0.0586 
-0.3241 
-0.0586 
-0.8517 
0.2069 
0.4724 
0.2103 
1.0000 
0.4724 
-0.2448 
-0.2448 
1.2621 
1.5103 
1.1379 
1.0000 
1.2655 
1.0035 
1.2655 
0.4759 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 . 0 0 0 0 0 0 . 0 0 0 0 0 
999 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
.0000 
,0000 
c 
c 
0 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
0 
0 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
0 
c 
0 
c 
c 
0 
V2000 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
0 
3 
0 
0 
0 
0 
0 
0 
0 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3 
2 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
636 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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File 15. The input file for flexible docking of Ligand E. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical_points 
chemical matching 
use ligand spheres 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
use clash overlap 
bump filter 
score molecules 
contact score primary 
contact score_secondary 
grid score primary 
grid score secondary 
grid_score_vdw scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
minimize anchor 
minimize flexible growth 
use_advanced_simplex parameters 
simplex max_cycles 
simplex score_converge 
simplex cycle converge 
simplex trans step 
simplex_rot_step 
simplex tors step 
fucoxanthin 
5coxselectedspheres 
.mol2 
flex 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
. sph 
500 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
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simplex anchor max iterations 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
500 
500 
no 
no 
0 
all 
vdw AMBER parm99.defn 
flex.defn 
flex drive.tbl 
File 15. The output file for flexible docking Ligand E. 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
fucoxanthin.mol2 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flex 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
500 
no 
no 
no 
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Flexxble Ligand Parameters 
flexible__ligand yes 
min_anchor_size 40 
num_anchor_orients_for_growth 100 
number_confs_for_next_growth 100 
use_internal_energy yes 
internal_energy_att_exp 6 
internal_energy_rep_exp 12 
internal_energy_dielectric 4.0 
use_clash_overlap no 
Bump Filter Parameters 
bump_filter no 
Master Score Parameters 
score_molecules yes 
Contact Score Paramters 
contact_score_primary no 
contact_score_secondary no 
Grid Score Parameters 
grid_score_primary yes 
grid_score_secondary yes 
grid_score_vdw_scale 1 
grid_score_es_scale 1 
grid_score_grid_prefix grid 
Simplex Minimization Parameters 
minimize_ligand 
minimize_anchor 
minimize_flexible_growth 
use_advanced_simplex_parameters 
simplex_max_cycles 
simplex_score_converge 
simplex_cycle_converge 
simplex_trans_step 
simplex_rot_step 
simplex_tors_step 
simplex anchor max iterations 
y e s 
y e s 
y e s 
1 
0 . 1 
1.0 
1.0 
0 . 1 
10.0 
500 
simplex_grow_max_iterations 
simplex_final_min_add_internal 
simplex_secondary_minimize_pose 
simplex_random_seed 
Atom Typing Parameters 
atom_model 
vdw_defn_file 
vdw_AMBER_parm99.defn 
flex_defn_file 
flex.defn 
flex_drive_file 
flex drive.tbl 
Initializing Library File Routines... 
Initializing Orienting Routines... 
Initializing Conformer Generator Routines... 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
Molecule: fucoxanthin 
Elapsed time: 2 seconds 
ERROR: Could not complete growth. 
Confirm grid box is large enough to contain 
ligand and try increasing max_orients. 
500 
no 
no 
0 
all 
1 Molecules Processed 
Total elapsed time: 2 seconds 
File 16. Input file for rigid docking of Ligand E. 
ligand atom file 
fucoxanthin.mol2 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
atom model 
vdw defn file 
flex defn file 
flex drive file 
rigid 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
all 
vdw_AMBER_parm99.defn 
flex.defn 
flex drive.tbl 
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File 16. Output file for rigid docking of Ligand E 
DOCK v6.0 
Released June 2006 
Copyright UCSF 
Molecule Library Parameters 
ligand atom file 
fucoxanthin.mol2 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
Orient Ligand Parameters 
orient ligand 
automated matching 
receptor site file 
5coxselectedspheres.sph 
max orientations 
critical points 
chemical matching 
use ligand spheres 
Flexible Ligand Parameters 
flexible ligand 
Bump Filter Parameters 
bump filter 
Master Score Parameters 
score molecules 
Contact Score Paramters 
contact score primary 
contact score secondary 
rigid 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
1000 
no 
no 
no 
no 
no 
yes 
no 
no 
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Grid Score Parameters 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
Simplex Minimization Parameters 
minimize ligand 
simplex max iterations 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
Atom Typing Parameters 
atom model 
vdw defn file 
vdw AMBER parm99.defn 
flex defn file 
flex.defn 
flex drive file 
flex drive.tbl 
Initializing Library File Routines... 
Initializing Orienting Routines... 
Initializing Grid Score Routines... 
Reading the energy grid from grid.nrg 
Molecule: fucoxanthin 
Elapsed time: 7 seconds 
Anchors: 1 
Orientations: 1000 
Conformations: 1000 
ERROR: Conformation could not be scored by DOCK. 
Conformation not completely within grid box. 
1 Molecules Processed 
Total elapsed time: 7 seconds 
yes 
yes 
1 
1 
grid 
yes 
1000 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
no 
no 
0 
all 
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5. DMS Program 
To generate spheres in the receptor structure COX-2, molecular surface is 
generated using the Dot Molecular Surface program (DMS). The input file for DMS is 
5coxrec_noH.pdb. The procedure for DMS was followed from the "Tutorial Generating 
Spheres" website which is a part of the official DOCK website; 
(http://dock.compbio.ucsf.edu/DOCK_6/tutorials/sphere_generation/generating_spheres. 
htm). To learn more about the DMS program one can access the website 
http://www.cgl.ucsf.edu/chimera/docs/UsersGuide/midas/dmsl .html. 
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APPENDIX B 
STRUCTURE-BASED DRUG DESIGN LAB MODULE 
DRUG TARGET IDENTIFICATION MODULE-1 
This module aims to identify the right drug target based on given information. It 
consists of details explaining the disease process and the drug targets associated with it 
along with their function. Upon reading the information given, there are questions at the 
end of the module for students to answer and then determine the best drug target. 
1.1 Background 
The structure-based drug design process involves detailed knowledge of binding 
sites of targets (such as proteins) associated with the disease. Every drug works based on 
structural interaction with the receptor or target molecule. The most common model is 
the one in which the drug molecule fits itself into the crevice of the target protein like a 
key in a lock. This strategy results in inhibition of the protein's function, and ultimately 
halts the progress of the disease. 
The first step in the structure-based drug design process starts with drug target 
identification. A drug target is a macromolecule that is essential for a disease causing 
agent to thrive. Every such agent has molecular components such as enzymes, and 
receptors that allow it to multiply or move to different parts of the body. To treat a 
disease, a specific macromolecule needs to be inactivated. In order to inactivate the drug 
target, the macromolecule or receptor needs to be identified based on how critical the 
target is to the disease process. The target should be located in a critical step of the 
metabolic pathway and its inhibition should consequently kill the disease causing 
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organism. Drug targets should be unique and specific so that no other pathway is 
suppressed. 
The disease state taken up for study in this module is Osteoarthritis. 
Osteoarthritis is a chronic disease of the joints involving breakdown of the joint tissue, 
primarily the cartilage. Cartilage is a tough elastic tissue covering the bone that acts as a 
shock absorber and keeps the bones from rubbing against each other. The entire joint is 
enclosed in a capsule that is lined by an inner membrane known as the synovial 
membrane. The membrane fills the space around the joints with a fluid called the 
synovial fluid. The synovial fluid nourishes the cartilage and keeps the joints lubricated 
making movement smooth and easy. Enclosing the joints are muscles, tendons and 
ligaments. These structures provide support and assist movement in the correct direction. 
Figure 1 shows the difference between a normal joint and a degenerative joint. 
Figure 1. Comparison of a normal joint and degenerative joints [diagram by author]. 
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The degeneration of the cartilage causes inflammation. Inflammation is one of 
the ways in which the body protects and repairs itself. The inflammatory reaction begins 
with tissue irritation. In response to the tissue irritation, white blood cells rush from the 
bloodstream to the area and heal the injury. They release enzymes and active products 
that affect the nearby cells and alter the blood circulation. The active, toxic products are 
prostaglandins and leukotrines. They are the potent producers of inflammation. They 
increase the flow of fluids and white blood cells around the area of inflammation and 
release more prostaglandins thereby feeding the process. The accumulation of these 
fluids and cells causes swelling along with pain. 
Treatment for osteoarthritis is aimed at controlling pain, improving and 
maintaining movement, and preventing degeneration of the joints. Pain control is a vital 
part of the treatment as the drugs help the patient gain control over the effects of the 
disease. Possible drug targets that were chosen are as follows. 
1. Cyclooxygenase enzyme-1 (COX-1) 
2. Cyclooxygenase enzyme-2 (COX-2) 
3. Prostaglandins 
4. Interleukin-1 receptor 
1.2 Drug Targets and their Contribution to Osteoarthritis 
Prostaglandins are hormones that act as chemical messengers inside the cell 
activating inflammatory responses and strengthening pain signals. They are unsaturated 
carboxylic acids consisting of a twenty-carbon skeleton and a five-member ring. They 
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are synthesized from the fatty acid arachidonate and initial reaction in their production is 
catalyzed by cyclooxygenase. 
There are two different cyclooxygenases, COX-1 and COX-2. Both of the 
enzymes perform the first step in production of prostaglandins by adding two oxygen 
molecules to arachidonate. The COX-1 and COX-2 enzymes are similar in structure and 
have the same substrate (arachidonate). The kinetics of both isoforms is similar but they 
obtain arachidonate from different sources. Figure 2 shows COX-1 (cyan) and COX-2 
(pink) structures viewed in the UCSF Chimera program. Figure 3 shows the COX-1 and 
COX-2 structures superimposed to illustrate that they are very similar. 
Figure 2. COX-1 and COX-2 structures viewed using UCSF Chimera. 
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Figure 3. COX-1 and COX-2 superimposed to illustrate similarity using UCSF Chimera. 
The COX-1 enzyme is a constitutive enzyme and is present in all cells in the 
endoplasmic reticulum. Its concentration is maintained at a constant level. The COX-1 
enzyme is a "housekeeping enzyme" involved in signaling, tissue homeostasis and 
cytoprotection. Most importantly, it produces prostaglandins in the stomach to help 
maintain the mucosal epithelium, and its inhibition causes gastric damage, bleeding and 
ulcers. COX-1 produced prostaglandins are required to maintain normal renal blood flow 
in impaired kidneys. Prostaglandins synthesized with the aid of COX-1 are essential for 
platelet function. 
COX-2 is an enzyme induced by pain that is produced spontaneously in the range 
of 10-80 amplification and its concentration reduces considerably after a few hours. It is 
found in high concentrations around macrophages, synovial cells, mucocytes, and 
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fibroblasts in response to inflammation. The prostaglandins produced by COX-2 increase 
inflammation when the system is trying to heal the inflamed area. Figure 3 shows a 
comparison of the COX-1 and COX-2 enzymes. 
Figure 4. Comparison of COX-1 and COX-2. 
The last drug target is the Interleukin-1 receptor that belongs to a family of 
cytokines. Cytokines are small secreted proteins which are capable of promoting 
inflammation. They contribute to bone degeneration in arthritis. The Interleukin-1 
receptor is present in the synovial lining of the joint, and the main function of this 
cytokine is to cause inflammation by activating the monocytes and macrophages. 
Interleukin-1 stimulates prostaglandins and nitric oxide production, and promotes joint 
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degradation. The expression of Interleukin-1 can be stimulated by various types of cell 
interactions (such as TNF, autocrine or paracrine). When one type of Cytokine is 
inhibited the other cytokines replace it and carry its function. Other cytokines having 
pro-inflammatory properties can also contribute to this pathological condition, and those 
having anti-inflammatory properties may be able to counteract the negative effects of the 
former on the disease process. 
1.3 Questions 
1. What are the symptoms of Osteoarthritis? 
2. What will happen if COX-1 mediated prostaglandin production is inhibited? 
3. What will happen if COX-2 mediated prostaglandin production is inhibited? 
4. Do you think it is possible to inhibit a specific class of prostaglandins? Explain. 
5. What is the role of cytokines in Osteoarthritis? 
6. Discuss the advantages and disadvantages of inhibiting COX-1 and COX-2. 
7. Which drug target(s) would you choose for inhibition and why? 
8. Perform a journal search on drug targets associated with Osteoarthritis and 
explain whether that drug target is inhibited. 
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STRUCTURE DETERMINATION MODULE-2 
The objective of this module is to determine, to view and to become familiar with 
the target structure. The module is comprised of a set of instructions to view the structure 
through the VEGA ZZ program and questions and activities to know the structural details 
and to get acquainted with the software. 
2.1 Background 
Structure determination is the second step in drug design process. This step is 
important because the chosen drug target is a constant factor until the end of the drug 
design process. The drug target needs to be edited for the docking module using the 
VEGA ZZ program; therefore students need to understand software. 
2.2 Procedure 
2.2.1 Step 1 - To obtain the structure of COX-2 from Protein Data Bank 
Each published 3D structure is assigned a four character identification code by 
Protein Data Bank. The pdb format is the most commonly used format for atomic 
coordinate files.The VEGA ZZ program is an interactive molecular graphics program and 
it needs an atomic co-ordinate file. For COX-2 structure, the pdb id is 5COX. The 
standard file name is 5COX.pdb. 
a) In one of your windows click on the link www.pdb.org. 
b) At the search engine, enter the four character protein identification code 
5 COX and click search. 
c) Detailed information will show up on the screen about COX-2 structure. 
d) Scroll down on the left hand side of the page and click on 
Download/Display file. 
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e) Click on "Complete with co-ordinates" and choose text. 
f) Enter a name for the file that will contain the co-ordinates for 5COX 
g) Whatever name is chosen, the file should have an extension '.pdb' for 
docking purpose. After entering the <name>.pdb click ok. 
2.2.2 Step 2- To View the COX-2 Structure 
a) Open the VEGA ZZ program. 
b) Scroll down and you will find a section entitled "enter the "PDB ID". 
Type "5-CGX" in it and click ok. 
c) Now you will see the protein molecule displayed on the VEGA ZZ screen. 
2.3 Questions 
1. How many different components does the structure contain? (try Color by 
Segment) 
2. Give the number of amino acids in this structure. 
3. How many bound components do you see in the 5 COX structure? 
4. Can you locate the active site(s) in the enzyme? How? 
5. What are the bound components called? 
6. What is the heme group made of? 
7. Find the structure of COX-1 from the PDB and display the complex in 
VEGA. Try to locate the ligands in the active site. Also try to read an 
article about this enzyme. 
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BINDING SITE IDENTIFICATION MODULE-3 
The objective of this module is to identify the binding site in the target structure. 
The students are required to perform a literature search using the keywords given in the 
procedure. 
3.1 Background 
Once the target structure is determined, the binding site needs to be identified. 
The binding site is a place in the target structure where the ligand can bind or dock itself. 
The binding site in enzymes is mostly the active site. It is a hollow cavity like structure 
and has hydrogen bond donors and hydrophobic characteristics. Only if the ligand binds 
to the target and is capable of inhibiting the target, is the ligand considered a lead 
compound. 
3.2 Step 1 - To perform a literature search to identify the binding site in the COX-2 
enzyme. 
a) Use the electronic database provided by the SJSU library 
b) Open any scientific databases you know of like Science Direct, Wiley 
Interscience, etc. 
c) Type the keywords "COX-2 + Active site + Location". 
d) Collect and research your data. 
3.3 Questions 
1. What residues are around binding site? 
2. There are two main active sites in the COX-2 structure. What are they? What 
are their functions? 
3. Which binding site would you choose for your drug design module and why? 
4. Point out and mark the active site in 5COX.pdb that you chose on the VEGA 
ZZ program. 
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TARGET - LIGAND DOCKING MODULE-4 
The objective of this module is to dock the ligand to the target structure using the 
UCSF DOCK software. The docking module is comprised of four mini modules. Each 
module has a set of instructions for the students to execute and answer the questions at 
the end. The four modules are 
1. Ligand and target molecule preparation module 
2. Sphere generation module 
3. Scoring grid module 
4. Docking module 
4.1 Background 
DOCK software predicts the binding modes of a small molecule-protein 
complex. The docking part is divided into a series of steps. Firstly, the potential sites of 
interest on the target molecule are identified. The site of interest includes the active site 
as well as other sites. This means that the software does not differentiate between the 
actual active site and the other potential sites. 
Secondly, the software generates spheres which fill the sites of interest chosen by 
DOCK. The centers of the spheres are assumed to be ligand atom positions. The spheres 
touch the surface of the molecule but do not intersect it. The spheres are allowed to 
overlap or intersect other spheres. Figure 1 shows how the spheres are arranged in a 
sample binding site. The cyan spheres are generated with the help of points from the 
molecular surface (green line). 
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Figure 1. Representation of the spheres arranged in a binding site. [Reprinted with 
permission from Dr.Irwin Kuntz and Dr.Therese Lang, "Tutorial: generating spheres", 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/sphere_generation/generating_spheres.ht 
m] 
After the spheres are generated, the sphere centers are "matched" with the ligand 
atoms in order to position a ligand in the active site. Many such sphere-ligand atom sets 
are formed using the longest distance heuristic method. The entire orientation of the 
ligand atom within the active site is calculated using the sphere-ligand atom sets [10]. 
The orientation of the ligand is evaluated using scoring grids. Scoring grids are 
pre -calculated energy information for each point of the target. Every point of the target 
has ligand-target binding energy and an electrostatic charge. As a result, interpolated 
receptor values are obtained. Finally when docking is performed, the ligand values are 
substituted and the orientation of the ligand is evaluated based on the lowest energy score 
for effective binding. 
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A standard method for docking described in the UCSF DOCK manual is 
followed. The crystal structure of COX-2 and the ligand is the starting data. To dock the 
target structure a step by step procedure was followed. 
• Molecule preparation ligand and receptor 
• Sphere generation in the receptor 
• Scoring grids for the receptor 
• Docking the receptor and ligand 
Prior to running DOCK it is a good idea to read the following documents from 
these webpages 
1. http://dock.compbio.ucsf.edu/DOCK_6/dock6_manual.htm 
2. http://dock.compbio.ucsf.edu/DOCK_6/tutorials/sphere_generation/generating_sp 
heres.htm 
3. http://dock.compbio.ucsf.edu/DOCK_6/tutorials/struct_prep/prepping_molecules. 
htm 
4. http://dock.compbio.ucsf.edu/DOCK_6/tutorials/grid_generation/generating_grid. 
html 
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The flowchart depicts the docking process in structure-based drag design. 
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LIGAND -RECEPTOR PREPARATION MODULE - 4.2 
4.2.1 Step 1 -To prepare the ligand and the receptor molecule for UCSF DOCK 
Please study the content in the following webpage before starting this module; 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/struct_prep/prepping_molecules.htm 
The purpose of this step is to prepare the target and the ligand molecule as an input to 
DOCK. The drug target is usually called a receptor in the docking stage. 
a) The receptor structure is a homodimer; only one subunit of COX-2 is 
required. Using the "Remove Segment" option in VEGA, delete all chains 
except one. 
b) Remove the water, ions and ligand from the receptor using the "Remove" 
option in the VEGA ZZ program. Add hydrogen atoms with the "Add" option 
in the "Edit" menu. 
c) Calculate the charges. Open the "Calculate" menu and click on "charges and 
potential". Choose Gasteiger charges to calculate. 
d) Save the receptor structure as 5coxreccharged.mol2 in a separate folder called 
"Structure". 
e) Remove hydrogen atoms from 5coxreccharged.mol2 and save it as 
5coxrec_noH.pdb. 
f) Obtain the ligand molecule, example LigandA from the ligand database in 
your system and import the mol file to the "Structure" folder. 
g) Add hydrogen to the ligand, calculate Gasteiger charges, and save it as 
ligcharged.mol2. Verify if the valency is complete as VEGA ZZ tends to over 
add hydrogen atoms. 
h) There are now 4 structure files, 5coxreccharged.mol2, 5coxrec_noH.pdb, 
ligand.mol2, and ligcharged.mol2. Work on one file at a time and always 
keep a backup folder. 
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SPHERE GENERATION MODULE - 4.3 
4.3.1 Step 1 - To generate spheres in the receptor structure using Sphgen, an accessory 
of DOCK. 
Prior to this session, it is essential to read the following webpages; 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/struct_prep/prepping_molecules. 
http://www.cgl.ucsf.edu/chimera/docs/UsersGuide/midas/dmsl.html 
a) In this session the students will use the DMS program and the Sphgen 
program to generate molecular surface and generate spheres on the receptor 
surface. 
b) As a prerequisite for generating spheres in the receptor structure, the 
molecular surface of the receptor is generated using the Dot Molecular 
Surface (DMS) program. 
c) The input for the dms is the 5coxrec_noH.pdb. Open the cygwin window 
and run the command "dms 5coxrec_noH.pdb -n -w 1.4 -v -o 5coxrec.ms" 
in which 
• -n is used to calculate normals for surface points 
• -w to change probe radius 
• 1.4 is the radius 
• v is the verbose 
• o is the output file . 
d) Save the output file as 5coxrec.ms. 
e) To generate spheres over the molecular surface of the receptor, a program 
called sphgen is used. 
f) Please note that Sphgen cannot handle more than 9999 spheres. In case of an 
error message, slice the receptor file to a smaller size around the periphery of 
the receptor structure using the VEGA ZZ program. 
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g) Use the "Remove atom" option in VEGA ZZ to remove atoms around the 
molecule. 
h) Then go to step [b] and run the DMS command. Once the output file 
(5coxrec.ms) is obtained, proceed to step [h]. 
i) Create a file called INSPH in the format shown below. (Demo version of 
DOCK).The file contains 5coxrec.ms file, parameters, and an output file name 
(5coxrec.sph). Store them all in a separate folder called "Sphere-site". 
File 1. The input file INSPH for sphere generation 
5coxrec 
R 
X 
0 
4 
1 
0 
0 
4 
5coxrec 
ms 
sph 
• R is the sphere outside of surface 
• X is the subset of surface points 
• 0.0 prevents generation of large spheres with close surface contacts 
• 4.0 is the maximum sphere radius in Angstroms 
• 1.4 is the minimum sphere radius in Angstroms 
j) Open the cygwin window. Run the command "sphgen" in the same folder 
that contains INSPH file. 
k) Two output files are generated of which one is the 5coxrec.sph file which 
contains spheres in clusters.The second output file is called the OUTSPH that 
contains calculation information. Save both files in a separate folder. 
1) View the 5coxrec.sph file in the VEGA ZZ program. Then open it in pdb 
format and split the files according to the number of clusters. For example, if 
the 5coxrec.sph file has 10 clusters, put each cluster into a separate file, hence 
you will get 10 cluster files. 
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m) Merge each cluster file with the receptor file (5coxrec_noH.pdb) individually 
to check if the spheres in the cluster were resting on the active site using the 
VEGA ZZ program. 
n) Based on the results of the literature search on the active site of COX-2, 
choose a cluster file that fills up the active site to the maximum. For example, 
if valine 523 is near the active site, make sure that the cluster you choose rests 
near that area. Save the chosen cluster file as 5coxselected spheres.sph 
4.3.2 Questions 
1. What is the concept behind DMS program? 
2. How does Spghen generate spheres on the receptor structure? 
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SCORING GRID MODULE -4.4 
4.4.1 Step 1 -To construct a box around the active site of the receptor structure. 
Please study the content in the following webpage before starting this module; 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/grid_generation/generating_grid.html 
Prior to grid generation, a box is constructed around the active site. The box 
specifies the location and size of the grid to be calculated. To create a box around the 
active site, a program called 'showbox' is used. 
a) Generate an input file (5coxbox.in) that contains default parameters, a cluster 
file and the output file name in the format shown in file2 (demo version of 
DOCK). 
b) Save the file 5coxbox.in in a separate folder called grid box. 
File 2. Input file 5coxbox.in 
y 
5 
5coxselectedspheres 
13 
5coxrec box.pdb 
. sph 
c) 
• Y- Yes (to construct box around the spheres) 
• 5 - Margin to be enclosed in Angstorms. 
• 13- Cluster number 
• 5coxrec_box.pdb - outputfile 
Run the command "showbox < 5coxbox.in>" and an outputfile 
5coxrec_box.pdb is generated and can be view in the VEGA ZZ program. 
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4.4.2 Step 2 - To generate energy scoring grids for the receptor structure. 
To compute energy scoring grid files, a program called Grid, an accessory of dock 
is used. The grid program pre-calculates the van der Waals and electrostatic interactions 
for the receptor active site enclosed by the grid box. The output from the calculation is 
stored as a scoring grid file. 
g=yy(4-4+332-^) 
,~« j> T\..s Equation 2 
MM rij rij *** 
• E is the intermolecular interaction energy in Kcal/mol 
• i and j are the ligand and the receptor atoms 
• a and b are the van der Waals repulsive and attractive exponents 
• Aij and Bij are the van der Waals repulsion and attraction parameters 
• r ij is the distance between atoms i and j 
• qi and oj is the point charges on the ligand i and receptor j atoms 
• D is the dielectric function 
• 332 is the factor to convert electrostatic energy to kcal/mol 
a) Create an input file called 5coxgrid.in, consisting of the receptor file, box file 
and vdw definition file along with the default parameters (obtained from demo 
version of DOCK). File 3 shows input file 5coxgrid.in for grid program. 
b) At any point if you have entered a wrong value for any parameter and would 
like to change it, you can edit the file and change the parameter value. 
c) Run the command grid - i 5coxgrid.in. Grid generates two binary files namely 
grid.bmp and grid.nrg. 
d) The grid.bmp file is a filter to remove ligand atoms that overlap on the 
receptor atoms during docking. The grid.nrg contains scoring grid 
information. 
133 
File 3. The input file 5coxgrid.in for grid program. 
compute_grids 
grid_spacing 
output_molecule 
contact_score 
energy_score 
energy_cutoff_distance 
atom_model 
attractive_exponent 
repulsive_exponent 
distance_dielectric 
dielectric_factor 
bump_filter 
bump_overlap 
receptor_file 
box_file 
vdw_definition_file 
score_grid_prefix 
yes 
0.3 
no 
no 
yes 
9999 
a 
6 
12 
yes 
4 
yes 
0.75 
5coxrec_charged.mol2 
5coxrec_box.pdb 
vdw_AMBER_parm99.defn 
grid 
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LIGAND-RECEPETOR DOCKING MODULE - 4.5 
4.5.1 Step 1 - To dock the ligand and the receptor using UCSF DOCK 
The purpose of this step is to bind the ligand to the receptor at the site chosen 
(active site) in the best orientation possible. The flexible docking mode is used in this 
module. Flexible docking relates to the ligand and the receptor molecules as objects that 
change their shape spatially during the docking process. 
a) Incorporate the files ligcharged.mol2, cluster file (5cox_selected spheres.sph), 
and the grid file (grid.nrg) into the input file called 5coxanchor_and_grow. in. 
b) The default parameters from the input file of the demo version of DOCK were 
also added. The input file 4 shows the 5coxanchor_and _grow. in is shown as 
follows. 
File 4. The input file 5coxanchor_and grow.in for docking. 
ligand atom file 
ligand outfile prefix 
limit max ligands 
read mol solvation 
write orientations 
write conformations 
skip molecule 
calculate rmsd 
rank ligands 
num scored conformers written 
orient ligand 
automated matching 
receptor site file 
max orientations 
critical points 
chemical matching 
use ligand spheres 
flexible ligand 
min anchor size 
num anchor orients for growth 
number confs for next growth 
use internal energy 
internal energy att exp 
internal energy rep exp 
internal energy dielectric 
ligandAcharged.mol2 
flex 
no 
no 
no 
no 
no 
no 
no 
1 
yes 
yes 
5coxselectedspheres.sph 
600 
no 
no 
no 
yes 
40 
100 
100 
yes 
6 
12 
4.0 
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use clash overlap 
bump filter 
score molecules 
contact score primary 
contact score secondary 
grid score primary 
grid score secondary 
grid score vdw scale 
grid score es scale 
grid score grid prefix 
minimize ligand 
minimize anchor 
minimize flexible growth 
use advanced simplex parameters 
simplex max cycles 
simplex score converge 
simplex cycle converge 
simplex trans step 
simplex rot step 
simplex tors step 
simplex anchor max iterations 
simplex grow max iterations 
simplex final min add internal 
simplex secondary minimize pose 
simplex random seed 
atom model 
vdw defn file 
flex defn file 
flex drive file 
no 
no 
yes 
no 
no 
yes 
yes 
1 
1 
grid 
yes 
yes 
yes 
no 
1 
0.1 
1.0 
1.0 
0.1 
10.0 
500 
500 
no 
no 
0 
all 
vdw AMBER_parm99.defn 
flex.defn 
flex drive.tbl 
c) Run the command "dock - i dock.in - i dock.out." The input file is dock.in 
(5coxanchor_and _grow. in) and dock.out is the output file. You can name the 
output file according to your choice. 
d) DOCK uses all the parameters from the input file for docking, and if some 
data is not available, DOCK will request it from the user. You can compare 
your dock.in file to the dock.in file in the demo version of DOCK and use the 
default values as your own. 
e) Please note that at any point if you have entered a wrong value for any 
parameter and would like to change it, you can edit the file and change the 
parameter value. 
f) Inspect the system for few minutes to make sure that DOCK is still running 
and to look for errors in the input. 
g) The default parameters could be changed for experimenting with the software. 
The output result is stored in a file called flexscored.mol2. At the end of your 
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output file, the lowest binding energy score of the best conformation of the 
ligand can be found. 
h) To view the docked output in VEGA, merge the receptor file 
5coxcharged.pdb with flexscored.mol2 file. Open flexscored.mol2 as pdb file 
in VEGA ZZ. 
i) To dock other ligands B, C, and D with the receptor follow the modules 4.2 
(g, h) and then 4.5. 
j) The ligands might generate an error message that it could not complete 
growth and it might suggest to increase the size of the grid box and to increase 
the ligand orientations. Try increasing the grid box and the maximum 
orientations in the input file. If the error message repeats, it could be because 
the binding site is too small or the ligand molecule is too large to fit inside the 
grid box and the active site. 
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POTENTIAL LEAD EVALUATION MODULE- 5 
This module aims to evaluate the ligands that were docked based on Lipinski's 
Rule of 5 and the number of rotatable bonds. It also explains the criterion for evaluating 
the ligands based on their binding affinity obtained from DOCK. Questions at the end of 
this module will help the students analyze ligands and come up with a potential lead. 
5.1 Background 
Once the ligand has been successfully identified, it is called the lead compound. 
It must be evaluated before proceeding to the preclinical trials. The lead is generally 
evaluated for its bioavailability, oral viability, chemical and physical stability, and ease of 
production. The final output file has a binding or grid score expressed as a sum of van 
der Waals forces and electrostatic interactions. The more negative the score is, the higher 
the binding affinity. Based on Veber's paper, the number of rotatable bonds should be 
less than 10 for oral bioavailability. Lipinski's Rule of 5 is followed for the lead drug 
evaluation. It is called Lipinski's Rule of 5 because all the four parameters are close to 5 
or multiples of 5. 
Lipinski's rule states that poor absorption or permeation is more likely when 
> There are more than five H-bond donors 
> The molecular weight is over 500 Da 
> The logP (partition coefficient) is over 5 
> The sums ofN's and O's are over 10 
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5.2 Step 1- To evaluate the docked ligand. 
Please read the journal article "Experimental and computational approaches to 
estimate solubility and permeability in drug discovery and development settings" by 
Lipinski et al. 
a) The chemical names of ligands will be disclosed. Tabulate the 
characteristics of the docked ligands based on the Lipinski's Rule of 5, the 
number of rotatable bond and the binding scores obtained from DOCK. 
b) Plot a partition co-efficient vs molecular weight graph from your table. 
c) Analyze your ligand and come up with the best ligand. 
5.3 Questions 
a) State the Lipinski's rule of 5. 
b) Why is a Log P greater than 5 unfavorable to the ligand? 
c) A lead drug for HIV infected patients is out in the market. It does not obey the 
Lipinski's rules. What are the disadvantages of that drug? 
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APPENDIX C 
INFORMATION AND ANSWER KEY FOR INSTRUCTORS 
DRUG TARGET IDENTIFICATION MODULE-1 
A) Choosing the Right Drug Target 
Analyzing the given drug targets, it is apparent that prostaglandins which are 
responsible for pain cannot be inhibited because they are produced by two different 
cyclooxygenases which carry out different functions altogether. The prostaglandins 
produced by COX-1 are essential for cytoprotection in the stomach, platelet aggregation 
and renal function. Prostaglandins produced by COX-2 cause inflammation. If inhibition 
of prostaglandins would not only stop inflammation but also stop positive functions of 
the body and cause damaging side effects. Hence prostaglandins cannot be used as a 
drug target. 
As for cytokines, they cannot be used as a drug target because specific blockage 
of the Interleukin-1 receptor causes other cytokines to replace its function. Therefore, it 
would not be a worthwhile strategy to inhibit the Interleukin-1 receptor. 
It is evident that the COX-1 enzyme also cannot be used as a drug target because 
inhibiting this cyclooxygenase isoform causes gastric damage, hemorrhageing and 
ulceration in the stomach. Inhibition of COX-1 also causes irregular blood flow in the 
kidney and platelet dysfunction in the circulatory system. The presence of COX-1 in all 
cells is important for cell function such as homeostasis. 
Although COX-1 and COX-2 enzymes are 60% homologous in structure they 
carry out different functions; one maintains normal cellular physiology while the other 
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causes pain. COX-2 enzyme is upregulated during inflammation and is present in 
insignificant amounts at other times in the human system; hence its inhibition would not 
affect the normal functions of the body. Since the aim of treatment is pain control with 
few side effects, COX-2 enzyme is the ideal drug target. Inhibition of the COX-2 
enzyme would result in anti-inflammatory and analgesic effects. 
B) Answer key for Drug Target Identification Module 
1. What are the symptoms of Osteoarthritis? 
Answer: Inflammation, tissue irritation and pain in the joints are the s symptoms of 
Osteoarthritis. 
2. What will happen if we inhibit prostaglandins that are produced by COX-1 ? 
Answer: COX-1 produced prostaglandins are required to maintain normal renal blood 
flow in impaired kidneys. The prostaglandins are essential for cytoprotection in the 
stomach, platelet aggregation and renal function. 
3. What will happen ifwe inhibit prostaglandins that are produced by COX-2? 
Answer: Prostaglandins produced by COX-2 cause inflammation. 
4. Do you think it is possible to inhibit a specific kind of prostaglandin? Explain. 
Answer: Prostaglandins which are responsible for pain, cannot be inhibited because 
they are produced by two different cyclooxygenases which carry out different functions 
altogether. The prostaglandins produced by COX-1 are essential for cytoprotection in the 
stomach, platelet aggregation and renal function. Prostaglandins produced by COX-2 
cause inflammation. If prostaglandins as a class are inhibited it would not only stop 
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inflammation but also stop normal cellular functions of the body and cause damaging 
side effects. Hence prostaglandins cannot be inhibited. 
5. What is the role of cytokines in Osteoarthritis? 
Answer: Cytokines are small secreted proteins which are pro-inflammatory. They 
contribute to the bone degeneration of arthritis. The Interleukin-1 receptor is present in 
the synovial lining of the joint. The main function of this particular cytokine is to cause 
inflammation by activating the monocytes and macrophages. 
6. Discuss disadvantages of inhibiting COX-1 and advantages of inhibiting COX-2. 
Answer: The COX-1 enzyme on inhibition causes gastric damage, hemorrhaging and 
ulceration in the stomach. The inhibition also causes irregular blood flow in the kidney 
and platelet dysfunction in the circulatory system. COX-2 enzyme is upregulated during 
inflammation and is present at other times in insignificant amounts in the human system; 
hence its inhibition would not affect the normal functions of the body. Inhibition of the 
COX-2 enzyme would result in anti-inflammatory and analgesic effects. 
7. Which drug target(s) is the root cause of inflammation and how? 
Answer: The COX-2 enzyme is an induced enzyme that is increased in concentration in 
the range of 10-80 in response to injury (its count reduces considerably after a few 
hours). It is found in high concentrations around macrophages, synovial cells, 
mucocytes, and fibroblasts in response to inflammation. COX-2 enzyme is characteristic 
of inflammation when the system is trying to heal the inflamed area. 
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STRUCTURE DETERMINATION MODULE-2 
A) Installation Requirements 
Install VEGA ZZ software for this module from the website: 
http://www.ddl.unimi.it/vega/download.htm 
B) Answer key to the Structure Determination Module 
1. How many different components does the structure contain? 
Answer: The COX-2 structure is a homodimer of identical subunits. The COX-2 
structure comprises of four protein chains. 
2. Give the number of aminoacids in this structure. 
Answer: 587 amino acids 
3. How many bound components do you see in the 5C0X structure? 
Answer: The structure contains four heme ligands and 12 N-acetyl glucosamine (NAG) 
trisaccharide ligands. 
4. Can you locate the active site(s) in the enzyme? How? 
Answer: The cyclooxygenase active site is located near valine 523. 
5. What is the heme group made of? 
Answer: The heme group is protoporphyrin IX containing iron (Fe). The metal free 
porphyrin combines with the ferrous ion to form the heme group. 
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BINDING SITE IDENTIFICATION MODULE-3 
A) Answer key Binding Site Identification Module 
1. What is an active site? 
Answer: The specific part at which the substarte attaches to the enzyme. 
2. What is the difference between active and binding site? 
Answer: They are the same more or less. 
3. What residues are around binding site? 
Answer: Valine 523, Phenyalanine 518, Valine 434, Tyrosine 385, Arginine 513. 
4. What are the two main active sites in the COX-2 structure? What are their 
functions? 
Answer: The COX-2 enzyme structure has two different active sites, the 
cyclooxygenase and the peroxidase active site. At the cyclooxygenase active site, 
arachidonate binds at the site to form prostaglandins. Peroxidase active site is needed 
to reduce a peroxy intermediate to an alcohol and to activate the heme groups that 
participate in the cyclooxygenase reaction. The cyclooxygenase active site is chosen to 
be the correct active site and will be used for the docking stage. 
5. Which binding site would you choose for your drug design module and why? 
Answer: The cyclooxygenase active site is located near valine 523, phenyalanine 518, 
valine 434, and tyrosine 385. Since the valine molecule is small, it leaves a gap causing 
a side pocket. This side pocket is the site of binding for many selective drugs. 
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6. Point out and mark the active site in 5COX.pdb that you chose on the VEGA ZZ 
program. 
Figure 2. COX-2 structure with active site surrounded by white residues. 
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TARGET - LIGAND DOCKING MODULE-4 
A. Installation Requirements for Target-Ligand Docking module 
a. To obtain Academic Software License for UCSF DOCK please access 
http://dock.compbio.ucsf.edu/Online_Licensing/dock_license_application.html 
b. After receiving the license for UCSF DOCK, you will receive the link to 
install the software. Follow the instructions based on the system configuration 
that SJSU provides and install the software. 
c. A copy of the DOCK reference manual is necessary to the instructors. 
B. The Ligands' Information 
The ligands' names are not disclosed to the students. The information about 
potential ligand compounds are obtained from KEGG Ligand Database. The chemical 
names and mol formats for four ligands are as follows. Please store them as Ligand A, B, 
C. and D in a folder called the ligand database. The actual names are as follows 
f. Ligand A = Acetyl salicylic acid 
g. Ligand B =Rofecoxib 
h. Ligand C = Celecoxib 
i. Ligand D = SC-558 (1-PHENYLSULFONAMIDE-3-TRIFLUORQMETHYL-5-
PARABROMOPHENYLPYRAZOLE ) 
j . Ligand E = Fucoxanthin 
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"f* COMPOUND: C01405 , Help j 
Entry :014Q5 Compound 
Name Aspirin;. . 
Acetylsaiicylic..' acid; 
2-Acetoxybenzesecarboxylic acid; 
Acetylsalicylate . 
Formula C91&04 
Mass 180.0423 
Structure 
Mdfile j .KCffifej ^DBsearchj 
Remark Sarjt as: 
Reaction R02942 
Enzyme .1.55 
Other OBs CAS:'50-78-2 
PubChem: 4594 
ChEBI: 15365 
3DMEI: B00284 
LinkDB Ail OBs 
KCF data . Show j 
N>,-i»...« , . . . , • >> 
Figure 1. Information for Ligand A in the KEGG Ligand Database. 
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File 1. The mol file for Ligand A. 
13 13 
20.2981 
21.5226 
19.0928 
20.2981 
21.5226 
22.7278 
19.0928 
21.5033 
19.0863 
20.2981 
23.9396 
25.1450 
23.9396 
1 2 1 
1 3 2 
1 4 1 
2 5 2 
2 6 1 
3 7 1 
4 8 1 
4 9 2 
5 10 1 
6 11 1 
11 12 1 
11 13 ' 2 
7 10 2 
M END 
0 0 
-15 
-16 
-16 
-14 
.-17 
-15 
-17 
-13 
-14 
-18 
-16 
-15 
-17 
0 
0 
0 
0 
0 
0 
0 
0 
o' 
0 . 
0 
0 
0 
0 0 
8105 
5029 
502 9 
6927 
9133 
8040 
9133 
9940 
0004 
6250 
4964 
7977 
9642 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
' 0'" 0 
0 0 
0 0 
0 0 
0 0-
0 0 
0 0 
0 0 0 0999 V2000 
0.0000 C 
0.0000 C 
0.0000 C 
0.0000 C 
0.0000 C 
0.0000 0 
0.0000 C 
0.0000 0 
0.0000 0 
0.0000 C 
0.0000 C 
0.0000 C 
0.0000 0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 , 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0, 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
o. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 . 
.0 
• o ' 
0 
0 
0 
0 
0 
0 
0 
0 
0 
•^ COMPOUND: C075I0 Help J 
Entry 
Name 
Formula 
Mass 
Structure 
Remark 
Other DBs 
LlnkDB 
KCF data 
C07590 Compound 
Rcfecoxib 
C17B1404S 
314.0613 
H3C^P 
oil 
To 
/\f\ \J ° 
C07590 
v MoHNe J • KCF file j M search] 
Same as : D00568 
CAS: 162011-90-7 
FjbChem: 9792 
ChEBI: 3887 
, AH DBs j 
v Show j 
Figure 2. Information of Ligand B in the KEGG Ligand Database. 
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Entry DQQ567 Drug 
Name Celecoxib {JAN/USAN/INN); 
Celebrex {TH) 
Formula C17H14F3H302S 
Mass 381.0759 
S t r u c t u r e 
Motfiiej JCCFfitej .pe search! 
^WWMtMHWWWy Vro^Wifl'WimKif.^y ^MtMifowmreWWiW^ 
Target ;yclooxygenase-2 (COX-2) inhibitor [HSA:5743], [EC:1.14.99.1] 
Activity Anti-inflannatory and analgesic [cyclooxygenase-2 inhibitor] 
Remark Same as: C07589 
Therapeutic category: 1143 
Pathway PATH-: map07112 1,2-Diphenyl substitution family 
Other DBs CAS: 169590^ 42.-5.... 
PubChem: 7847633 
LinkDB All DBsj 
KCF d a t a Show 
Figure 3. Information of Ligand C in the KEGG Ligand Database. 
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File 14. The mol file for Ligand E. 
I S I S H O S T 0 3 2 4 0 4 2 3 2 0 2 D 1 
48 50 0 
- 4 . 6 4 1 4 
- 4 . 6 4 1 4 
- 4 . 1 9 3 1 
- 5 . 1 0 0 0 
- 4 . 1 9 3 1 
- 5 . 1 0 0 0 
- 4 . 1 9 3 1 
- 5 . 5 6 5 5 
- 5 . 3 6 9 0 
- 4 . 8 4 1 4 
- 3 . 7 3 4 5 
- 5 . 5 6 5 5 
- 3 . 2 8 2 8 
- 3 . 7 4 1 4 • 
- 6 . 0 0 0 0 
- 2 . 8 2 7 6 
- 3 . 2 8 9 7 
- 2 . 3 7 2 4 
- 1 . 9 1 7 2 
- 1 . 4 6 2 1 
- 1 . 0 0 6 9 
- 1 . 4 6 5 5 
- 0 . 5 5 1 7 
- 0 . 0 9 6 6 
0 . 3 5 5 2 
0 . 8 1 0 3 
1 . 2 6 2 1 
0 . 8 0 6 9 
1 . 7 2 0 7 
2 . 1 7 2 4 
2 . 6 2 7 6 
3 . 0 8 6 2 
2 . 6 2 4 1 
3 . 5 3 7 9 
3 . 9 8 9 7 
4 . 4 4 4 8 
3 . 9 8 9 7 
4 . 9 0 3 4 
4 . 7 0 6 9 
4 . 1 7 9 3 
4 . 4 4 4 8 
3 . 8 5 1 7 
3 . 4 7 9 3 
4 . 9 0 3 4 
5 . 3 6 2 1 
5 . 8 1 3 8 
6 . 2 6 5 5 
5 . 8 0 6 9 
1 2 1 0 
1 3 1 6 
1 4 1 0 
1 5 1 1 
2 6 1 0 
2 7 1 1 
4 8 1 0 
1 0 
- 0 . 3 4 8 3 
- 0 . 8 7 5 9 
- 0 . 6 1 0 3 
- 0 . 0 8 2 8 
- 0 . 0 8 2 8 
- 1 . 1 3 7 9 
- 1 . 1 3 7 9 
- 0 . 3 4 8 3 
0 . 3 7 2 4 
0 . 3 7 2 4 
- 0 . 3 4 4 8 
- 0 . 8 7 5 9 
- 0 . 0 7 9 3 
- 0 . 8 6 9 0 
- 1 . 1 3 4 5 
- 0 . 3 4 1 4 
0 . 4 4 8 3 
- 0 . 0 7 5 9 
- 0 . 3 3 7 9 
- 0 . 0 7 2 4 
- 0 . 3 3 4 5 
0 . 4 5 1 7 , 
- 0 . 0 7 2 4 
- 0 . 3 3 4 5 
- 0 . 0 6 9 0 
- 0 . 3 3 1 0 
- 0 . 0 6 5 5 
- 0 . 8 5 8 6 
- 0 . 3 2 7 6 
- 0 . 0 5 8 6 
- 0 . 3 2 4 1 
- 0 . 0 5 8 6 -
- 0 . 8 5 1 7 
0 . 2 0 6 9 
0 . 4 7 2 4 . 
0 . 2 1 0 3 
1 . 0 0 0 0 
0 . 4 7 2 4 
- 0 . 2 4 4 8 
- 0 . 2 4 4 8 
1 . 2 6 2 1 
1 . 5 1 0 3 
1 . 1 3 7 9 
1 . 0 0 0 0 
1 . 2 6 5 5 
1 . 0 0 3 5 
1 . 2 6 5 5 
0 . 4 7 5 9 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
1 . 0 0 0 0 0 
999 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0^.0000 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
0 . 0 0 0 0 
. 0 . 0 0 0 0 
c 
c 
0 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
0 
0 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
0 
c 
0 
c 
c 
0 
0 . 0 0 0 0 0 
V2000 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
0 
3 
0 
0 
0 
0 
0 
0 
0 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3 
2 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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SPHERE GENERATION MODULE - 4.3 
A) Installation Requirements for Sphere generation module 
Please install the Dot Molecular Surface program (DMS) from the website 
http://www.cgl.ucsf.edu/chimera/docs/UsersGuide/midas/dmsl.html. The procedure for 
DMS was followed from the "Tutorial Generating Spheres" website which is a part of the 
official DOCK website; 
http://dock.compbio.ucsf.edu/DOCK_6/tutorials/sphere_generation/generating_spheres. 
This website gives clear instructions regarding molecular surface generation and 
sphere genearation. The output file (5coxrec.sph file) obtained from sphgen was edited by 
splitting into 49 different cluster files. The 5coxrec.sph file is shown in pdb format in 
Figure 1. 
Figure 1. The Scoxrec.sph file is shown in pdb format. 
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Then the cluster files are merged with the modified receptor file 
(5coxrec_noH.pdb) individually. The VEGA ZZ program is used to check if the spheres 
in the cluster were resting on the active site. It is found that the 5th cluster file, matches 
with the active site of the receptor. 
Please give fifth cluster file shown in File 1 to students as they might have chosen 
a different cluster file. The cluster file should be saved as 5coxselectedspheres.sph. 
File 1. The fifth cluster file. 
cluster ' 
564 
1407 
1408 
1432 
1433 
1435 
1440 
1455 
1456 
1494 
1713 
1724 
1748 
1750 
2320 
2345 
2351 
2355 
2356 
2375 
2376 
2378 
2379 
2382 
2405 
2412 
2413 
2414 
25 
24 
25 
24 
24 
24 
24 
26 
24 
26 
25 
25 
24 
24 
22 
23 
2,4 
24 
24 
24 
24 
24 
24 
24 
27 
28 
27 
29 
5 ' ' 
47775 
89094 
53015 
32610 
53161 
48589 
55522 
13715 
61458 
41505 
27725 
48431 
78060 
86185 
65622. 
'89269 
74022 
42115 
56858 
.12689 
56398 
70856 
87683 
49579 
95099 
46263 
56845 
08758 
number of 
21 
.23 
23 
24 
23 
23 
21 
21 
20 
21 
24 
24 
23 
24 
23 
23 
22 
21 
23 
23 
23 
21 
23 
22 
23 
22 
21 
23 
24536 
01594 
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10 
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11 
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12 
14 
15 
15 
15 
18 
16 
13414 
34170 
41222 
15387 
48500 
64364 
15050 
92801 
57876 
82538 
50218 
92778 
08374 
70872 
64984 
35615 
03681 
17635 
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Figure 2 shows the spheres of the cluster file merging with the active site of the 
receptor file. The fifth cluster contains 28 spheres shown as solid spheres. The tubular 
structures are valine 523 (yellow) and phenylalanine 518 (purple) atoms which are near 
the active site. 
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Figure 2. Spheres of the cluster file resting on the active site 
B) Answer key to the sphere generation module 
1. What is the concept behind DMS program? 
Answer: The DMS program generates molecular surface based on an algorithm 
developed by Richards and Conolly. It is viewed as van der Waals surface of a molecule 
except that the crevices are softened and the cavities are included. 
2. How does Spghen generate spheres on the receptor structure? 
Answer: The software generates spheres which fill the sites of interest chosen by DOCK. 
The centers of the spheres are assumed to be ligand atom positions. The spheres touch 
the surface of the molecule but do not intersect it. The spheres are allowed to overlap or 
intersect other spheres. After the spheres are generated, the sphere centers are "matched" 
with the ligand atoms in order to position a ligand in the active site. Many such sphere-
ligand atom sets are formed using the longest distance heuristic method. 
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LIGAND-RECEPTOR DOCKING MODULE 
A) Table 1. The binding scores of the docked ligand. 
Ligand 
Ligand A(acetyl 
salicylic acid) 
Ligand B(rofecoxib) 
Ligand C(celecoxib) 
Ligand D(SC-558) 
Ligand E(fucoxanthin) 
Grid score for flexible 
docking Kcal/mol 
-38.7330 
-40.356 
-34.592 
- 40.7028 
Error: Could not complete 
growth. Confirm grid box 
is large enough to contain 
ligand 
Grid score for rigid 
docking 
Kcal/mol 
-36.6905 
-35.400 
-14.554 
13.4299 
Error: Conformation 
could not be scored by 
DOCK. Conformation 
not completely within 
grid box. 
POTENTIAL LEAD EVALUATION MODULE- 5 
A) Table shows the Lipinski?s rule of 5 characteristics for the docked ligands. 
Ligand 
Ligand A 
Ligand B 
Ligand C 
Ligand D 
Ligand 
E(fucoxanthin) 
Xlogp 
Partition 
coefficient 
1.4 
3.2 
3.9 
4.2 
7.9 
OH+NH 
H-bond 
donors 
1 
0 
* ' " . : • ' " 
1 
2 
MolWt 
g/mol 
180.16 
314.357 
381.373 
446.243 
658.906 
N+O 
H-bond 
acceptors 
4 
4 
8 
8 
6 
Rotatable 
bonds 
3 
3 
3 
3 
12 
Alert 1: 
good; 0: 
poor 
1 
1 
1 
1 
0 
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B) Answer key to potential lead evaluation module. 
1. State the Lipinski' s rule of 5. 
Answer: Lipinski's rule states that poor absorption or permeation is more likely 
when 
> There are more than five H-bond donors 
> The molecular weight is over 500 Da 
> The logP (partition coefficient) is over 5 
> The sums ofN's and O's are over 10 
2. Why is a Log P greater than 5 unfavorable to the ligand? 
Answer: It is known that permeability decreases with high molecular weight, 
resulting in less bio absorption. MLog P is the partition coefficient and is found 
to be directly proportional to the molecular weight. As the molecular weight 
increases, the log P values become larger, indicating less permeability. 
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™
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-
5 
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Graph showing logP vs. molecular weight 
logP vs Mol wt 
B 
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3. A lead drug for HIV infected patients is out in the market. It does not obey the 
Lipinski's rules. What are the disadvantages of that drug? 
Answer: If a lead drug does not obey the Lipinski's rule of 5, it means that the 
drug would not be absorbed properly. Even if they are absorbed, it may not 
survive when it enters the bloodstream. As HIV patients have weak immune 
systems it is not a good idea to give the drug to them, hence it is not a good drug. 
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